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1.Introduction 
 
1.1 Siglecs   
1.1.1 The Siglec receptor family 
Lectins are carbohydrate-binding proteins that are widespread present in pro and 
eukaryotic cells. Within mammals they are responsible for functions such as cell-cell 
interactions, protein trafficking or defense reactions (1, 2). Siglecs are a receptor 
protein subgroup of the immunoglobulin superfamily (IgSF) (3). Like most of the lectins 
the members of this family are linked to the mediation and contribution of various 
biological processes (4). Among others certain members of this family have been 
shown to recognize complex carbohydrate molecules (5). To the first proteins of the 
Siglec receptor group that were discovered belong sialoadhesin on macrophages and 
cluster of differentiation (CD) 22 on mature B-cells. Independent work from different 
groups described an abolishment of sialoadhesin and CD22 mediated cell-cell 
interactions in cells treated with sialidases (5-7). Since the cell surface sialic acids 
were missing it was concluded that certain sialic acids were ligands for these 
membrane proteins. Further confirmation of this hypothesis was achieved by 
experiments with purified sialoadhesin and recombinant forms of CD22 domains (8, 9). 
Based on these findings various groups demonstrated that the structure of the sialic 
acids is of particular importance for the recognition by cells (10). Due to their structural 
homology CD33, mammalian myelin-associated glycoprotein (11) and avian Schwann 
cell myelin protein (SMP) were later identified to recognize sialic acids as well (12, 13). 
The fact that a group of lectins belonging to the IgSF was able to specifically detect 
glycan molecules led to the generic name I-type lectin (14). Since this name did not 
allow proper sub-classification of the sialic acid recognizing proteins the term Siglecs 
was introduced to describe this family of sialic acid binding lectins (15).  
Sialoadhesin being the first molecule discovered to bind sialic acids received the name 
Siglec-1. CD22 and CD33 were categorized as Siglec-2 and Siglec-3 while MAG and 
SMP were put together as Siglec-4a and -4b. Later discovered Siglecs were named in 
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the order of discovery. For human Siglecs numbers were chosen while rodent Siglecs 
received capital letters.  
 
1.1.2 The Siglec subfamilies  
The Siglec receptors are based on sequence similarity and evolutionary conversion 
divided in two distinct subfamilies. Siglec-1, 2, 4 and the recently discovered Siglec-15 
represent an evolutionary conserved group (16). These Siglecs are only distantly 
related (25-30% sequence identity) and have clear orthologes in all of the Siglec 
expressing species (17).   
In contrast, the second group named CD33 related Siglecs is rapidly evolving and 
presents species dependent divergent features. The CD33 related Siglecs include 
Siglec-3 (CD33), -5, -6, -7, -8, -9, -10, -11, -12, -14 and -16 in human beings and 
murine CD33, Siglec-E, -F, -G and –H in mice. The sequence identity within the CD33 
related Siglecs is between 50-99% (17). In contrast to the conserved group however, 
these Siglecs are influenced by various gene-altering mechanisms including deletion 
and exon shuffling. Angata and co-workers hypothesized that this could be the result of 
an evolutionary arms race between hosts and pathogens within the field of sialic acid 
recognition (17).  
Apart from Siglec-4 and -6, the expression of Siglecs is mainly located in cells of the 
haematopoietic and immune system (16). Some of the Siglecs are linked to a specific 
cell type. Siglec-1 and -2 for example are strictly present on macrophages or B-cells 
(18). However, most of the CD33 related Siglecs are more widespread distributed 
within the innate immune system. Mouse Siglec-E and human Siglec-9 present a 
widespread expression pattern on various leukocyte subsets, being so far described 
on monocytes, macrophages, neutrophiles, dendritic cells and in case of Siglec-E 
mouse microglia (19, 20). Besides T-cells the majority of immune cells express one or 
several Siglecs (21). Especially, cells of the innate immune system are equipped with 
several Siglecs within their receptor arsenal (21). Microglia present the murine Siglec-
E, -F and H (19, 22) and the human Siglec-3, -11 and -16 on their cell surface (13, 23, 
24). 
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1.1.3. Structural features and functions of Siglecs 
Siglecs developed 180 million years ago (25). Inhibitory Siglecs manifested 
themselves in greater numbers while only few activating (Siglec-14, 15, 16 in humans) 
Siglecs can be found. Pressure to de-select the activating Siglecs was coming from the 
fact that immune reactions would be out of line. Reaching a balance between 
activation and inhibition was necessary. 
A common feature of all Siglecs known to date appears to be that they are single-pass 
type 1 integral membrane proteins that exhibit an extracellular N-terminal V-set 
immuneglobulin domain followed by a variable amount of C2-set domains. The V-set 
domain is considered to be mainly responsible for the ability of the Siglecs to recognize 
sialic acids while the C2-sets are functioning as spacers. The process of ligand 
recognition by Siglecs is described in detail in chapter 1.1.4. 
Siglec receptor expressing immune cells transmit their intracellular signals via 
immunoreceptor tyrosine-based activation motif (ITAM) or immunoreceptor tyrosine-
based inhibition motif (ITIM) and ITIM-like motif signaling cascades. A line of ITAM-
signaling receptors including mouse Siglec-H as well as human Siglec-14, -15 and -16 
interact with the ITAM-containing adaptor protein DAP12 via charged amino acids that 
are located in their transmembrane regions. As a consequence, Src family tyrosine 
kinases phosphorylate the ITAM protein providing docking sites for Spleen tyrosine 
kinases (Syk). Subsequently, these kinases activate a line of downstream factors 
(Figure.1.1) responsible for actions like phagocytosis, cytokine release and cell 
migration (26). The ITAM signaling cascade is counter regulated by ITIM signaling 
receptors (Figure 1.1). Upon ligand binding these motifs get phosphorylated via Src 
family tyrosine kinases. As a result, high affinity binding sites for Src homology region 
2 domain-containing phosphatase 1 (SHP1) a Src homology region 2 (SH2) containing 
ubiquitously expressed tyrosine-specific protein phosphatase, are made available. 
Past activation SHP-1 dephosphorylates key components of ITAM regulated signaling 
pathways. Important functions of the ITIM mediated effects are the modulation of 
leukocyte behavior by counteracting ITAM signaling and modulation of anti-
inflammatory reactions (27, 28). 
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Figure 1.1: Pathway of ITAM and ITIM signaling in immune cells. Past ligand binding ITAM expressing 
cells execute the phosphorylation of intracellular adaptor proteins. As a consequence syk kinases 
phosphorylate a line of downstream proteins that orchestrate among others actin reorganization, which 
is the requirement for migration and phagocytosis. The majority of Siglec receptors are transmitting their 
signals via the ITAM counter-regulating ITIM pathway. This is done by activation of SHP1, which 
dephosphorylates and thereby inactivates key elements of the ITAM signaling cascade. Adapted from 
Linnartz and Neumann, 2013. 
 
The majority of the CD33 related Siglecs plus CD22 act via ITIM signaling cascades 
while mouse Siglec-H as well as human Siglec-14, -15 and -16 act via the ITAM 
containing adapter protein DAP12 (29-31). Consequently, the functions of the 
respective Siglecs are determined by their signaling capacities.  
A Siglec-E antibody cross-linking experiment revealed an inhibited production of the 
pro-inflammatory cytokines tumor necrosis factor (TNF)-α and interleukin (IL)-6. 
Comparable findings were found in Siglec-9 over-expressing macrophages (32). Both 
Siglecs signal via ITIM structures. Furthermore, Toll-like receptors (TLRs) have been 
shown to up-regulate the Siglec-E expression on macrophages after 
lipopolysaccharide (LPS) stimulation (33, 34). A regulatory feedback mechanism that 
gets activated in order to control the inflammatory response and prevent harm from 
sepsis was considered (34). On the other hand, the ITAM associated Siglec-14 was 
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found to be capable to enhance and thereby worsen inflammatory reactions in patients 
suffering from chronic obstructive pulmonary disease (35). 
In general, there is a clear connection with ITIM-linked Siglecs counteracting activation 
signals from ITAM associated cells thereby controlling and modulating various immune 
and homeostasis relevant processes. 
 
1.1.4 Sialic acid recognition by Siglecs 
All nucleated cells are covered on their surface with a dense layer of different sugar 
chains also referred to as glycans, which in total are called the glycome. In a variety of 
tissues the outer part of the glycans of the deuterostome lineage of animals 
(vertebrates and a few higher invertebrates) and of some bacteria is covered by sialic 
acids (36). The different versions of sialic acids form a subclass of the glycome 
referred to as the sialome. The sialome is defined as the total complement of sialic 
acid types and linkages (37). Sialic acids are derived from the nonulosonic acid family 
(38, 39). They are ubiquitously expressed on the membranes of vertebrate cells. Due 
to this outermost location the sialic acid containing cell layer is extremely important for 
cell and tissue interaction. Furthermore, sialic acids are also required during embryonic 
development (40) and for providing signals for self-recognition to complement factors 
and Siglecs (41). Generally, sialic acids are consisting of nine-carbon alpha-keto 
aldonic acids. They are synthesized by condensation of a neutral six-carbon molecule 
with a three-carbon pyruvate. While five or six-carbon structures can be found 
throughout the different species sialic acids are with the exception of a very few 
bacteria the only occurring nine-carbon sugars in nature (36). The C-5 position of the 
sialic acids can be linked to an N-acetyl group resulting in N-acetylneuraminic 
(Neu5Ac) or a hydroxyl group resulting in 2-keto-3deoxy-D-glycero-D-galacto-2-
nononic acid (Kdn). The 5-N-acetyl group can also be hydroxylated, resulting in N-
glycolylneuraminic acid (Neu5Gc). Less commonly, the 5-amino group is not acylated, 
resulting in neuraminic acid (Neu).   
These four sugars (Neu5Ac, Neu5Gc, Kdn, and Neu) represent the main molecules of 
the sialic acid family which in total includes over 40 neuraminic acid derivatives (42). 
They can be linked in a α2-3, α2-6 or α2-8 manner by sialyltransferases. 
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Figure 1.2: Structure of N-acetylneuraminic acid. Located on top of glycans or gangliosides on the 
surface of cells. When serving as ligand for Siglecs the molecule is linked via its C2 atom with the C3, 
C6 or C8 atom of its neighboring sialic acid. The kind of linkage of the sialic acids is crucial for the 
selective recognition by Siglec receptors. Residues at the C5 atom like an acetylated or hydroxylated 
group determine the basic subgroups of sialic acids (Neu, Neu5Ac, Neu5Gc and Kdn). Adapted from 
Angata and Varki, 2010. 
 
The most common and most significant member of the family is the Neu5Ac (42). 
Furthermore, the individual Neu5Ac can be connected in a chain up to a length of 180 
molecules (Figure 1.2). In some way the majority of the Siglecs recognize Neu5Ac but 
they differ in their specificity and affinity for type and the linkage of the particular sialic 
acid molecule. These polysialic acids (PSA) represent therefore endogenous ligands to 
the Siglec receptors. 
The glycan-binding by Siglecs is mediated via their extracellular V-set domain (3). 
Ligand binding depends on several molecular interactions between conserved 
residues in the V-set domain and the chemical structure of the sialic acids. Certain 
amino acids of the V-set domain appear to be important for the specific recognition of 
sialic acids. Of special importance is a conserved arginine residue, which is essential 
for the binding of the sialic acids to the Siglecs (21). This amino acid part is forming a 
salt bridge with sialic acid carboxylate groups and thereby mediating binding of the 
sialic acids to the receptor (42).  
By binding to the respective Siglec receptor sialic acids act as self-associated 
molecular patterns (SAMPs) (43). Recognizing these SAMPs ITIM associated Siglecs 
act as innate immune modulators that are orchestrating inflammatory reactions in 
particular after tissue damage (44). The ITAM associated Siglecs which are kind of 
counteracting the effect of the ITIM bearing receptors are considered to be a 
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evolutionary response of the immune system towards certain bacterial strains that 
developed the ability to present sialic acids on their surface that can be recognized by 
ITIM associated Siglecs (45).   
 
1.1.5 Siglec-H 
A lot of the Siglec related research done so far was aiming at the ITIM linked Siglec 
receptors. However, to get a more complete idea of how Siglecs work within the 
immune system it is also important to study the group of ITAM associated Siglecs. The 
Siglec-H gene was discovered in 2006 by a group of investigators that described it to 
be a cell surface marker on murine plasmacytoid dendritic cells (PDC) (29, 46). They 
also identified the Siglec-H protein on subsets of macrophages in spleen and lymph 
nodes. However, no expression of Siglec-H on microglia has been reported so far (47). 
Compared to most of the other members of the receptor family Siglec-H is very small 
and misses its own cytoplasmic signaling domain. Instead, it is linked to the ITAM 
containing adapter protein DAP12. Until now, no carbohydrate structure that could 
serve as a potential ligand for Siglec-H has been discovered. Although his exact 
function is still not clear there is accumulating evidence that Siglec-H might act as an 
endocytic receptor (47). Siglec-H specific engulfment of antigens by plasmacytoid 
dendritic cells and subsequent presentation to T-cells has been described recently 
(48). Furthermore, extensive involvement of Siglec-H in T-cell immune activation and 
tumor inhibition has been documented over the past few years as well (49). At the 
moment the overwhelming majority of available data deals with Siglec-H in PDCs but 
not in the CNS. 
 
1.1.6 Siglec-11 
Varki and co-workers first described the CD33 related human Siglec-11 in 2002. The 
receptor is distinct located in various tissues. Siglec-11 was found in Kupffer cells in 
the liver, intestinal lamina propria macrophages, microglia cells in the central nervous 
system (CNS), and perifollicular cells in the spleen, as well as in cells from tonsils and 
appendix (23). The structure of Siglec-11 is composed of five extracellular IgG-like 
domains, one single-pass transmembrane domain and a cytosolic part that is linked to 
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ITIM structures (23). Intracellular signaling takes place like in the other members of this 
receptor group via recruitment SHP 1 and 2 units.  
Siglec-11 shares over 99% of sequence identity at the first two Ig-like domains to the 
recently discovered ITAM associated Siglec-16 (24, 50). Siglec-16 is likely to have 
developed by a gene conversion event of the uncharged transmembrane domain and 
inhibitory cytoplasmic tail of the primordial Siglec-11 gen. Although it is discussed to be 
a "paired" Siglec to Siglec-11 that is balancing the functions of microglia there are no 
functional data on Siglec-16 published at the moment (24).  
Siglec-E in mice and human Siglec-10 are the functional most similar receptors to 
Siglec-11 known so far. Siglec-11 shows 90% gene sequence homology to the 
extracellular domains of Siglec-10. However, while Siglec-10 binds to both α2-3- and 
α2-6-linked sialic acids, binding of α2.8-linked sialic acid preferentially consisting of 
three monomers to Siglec-11 has been described (23). Since Siglec-11 binds uniquely 
to α2-8 linked sialic acids the strict focus on this sort of sialic acid distinguishes this 
receptor from other human Siglecs (23). In vitro experiments using murine primary 
microglia that were transduced with a Siglec-11 lentiviral vector revealed 
neuroprotective and immunomodulating features of Siglec-11. The release of pro-
inflammatory cytokines and the phagocytosis of neuronal material were reduced 
following cross-linking with a flag-specific antibody (51). Furthermore, co-culture of 
Siglec-11 transduced microglia with neurons resulted in significant less neuronal cell 
death compared to the respective controls (51). Therefore, the authors considered 
Siglec-11 a promising target for further studies and highlighted the potential for 
therapeutic approaches of this receptor protein after stimulation. 
 
1.2 Microglia within the innate immune system 
1.2.1 The innate immune system 
The mammalian immune system has developed during evolution to fight off invasions 
by microorganisms or parasites. Moreover, the elimination of degenerated cells and 
inhibition of tumor development is another important feature. Through the critically 
involved cell types and essential mechanisms, the defense system can be divided into 
innate and adaptive immunity. Innate immunity serves as a first line of defense with 
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cells rapidly responding to invading microorganisms or abnormal cells/tissues by 
triggering inflammatory, cytotoxic and phagocytotic reactions. The identification of 
altered host cells, viral, bacterial, fungal or protozoic pathogens is largely based on 
critical structural motifs. Innate immune cells express receptors with a broad specificity 
against these diverse motifs. These structures are referred to as pathogen-associated 
molecular patterns (PAMPs) (52). They represent an assortment of evolutionary 
conserved structures that are most critical for the vitality of the microbes and thus exert 
only minor variation. Innate immune cells, in turn, got equipped with complementary 
receptor systems called pattern recognition receptors (PRRs) that are able to sense 
such characteristic structures (52-54).  
The adaptive immune system can recognize, neutralize, eliminate and remember an 
enormous variety of antigenic structures including tumor cells with a high degree of 
specificity. Both the innate and adaptive immune systems mutually cooperate to mount 
and govern efficient host defense activities. Failure in targeting, executing or 
controlling can either result in insufficient protection and tumor development or 
autoimmune diseases. 
 
1.2.2 Microglia 
Microglial cells are a specialized type of tissue macrophages within the CNS. These 
cells also known as brain macrophages (55) represent an important part of the innate 
immune system and guarantee its defense capacity. They represent the main part of 
the innate immune system in the immune privileged area that is the CNS. Del Rio-
Hortega first described microglial cells in 1932. The origin of microglial cells was a 
matter of debate for some time. In 2010 it was shown that in contrast to previous 
assumptions post-natal hematopoietic progenitors do not significantly contribute to 
microglia homeostasis in the adult brain compartment. Instead adult microglia derive 
from primitive myeloid progenitors that arise before embryonic age E8.0 (56). 
Microglial cells act similar to other kinds of macrophages within the human (and 
generally the mammalian) body. Their main functions in the adult brain are the 
homeostatic surveillance and, if required, detection and neutralization of pathogens, 
support of endangered neurons and phagocytotic clearance of damaged tissue 
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constituents. Additionally, they can produce and regulate the release of cytokines and 
chemokines that trigger an inflammatory reaction or attract and activate peripheral 
immune cells. Microglia, like macrophages are antigen-presenting cells that interact 
with T cells to recruit the aid of the adaptive immunity (57). To execute the various 
functions, microglial cells need to become activated. Under normal conditions, they are 
in a resting state, scanning their environment for signs of normal CNS function and 
integrity (55). Upon signs for homeostatic disturbance, they can rapidly transform to an 
activated state. In their activated form, microglial cells express increased levels of 
surface structures for cell-cell and cell-matrix interactions, such as major 
histocompatibility complexes (MHC) class I and II or cell adhesion molecules, as well 
as an array of receptor proteins for soluble factors (55). They can mediate the release 
of a line of signal and effector molecules, ranging from small lipid mediators to 
cytokines and enzymes. 
Microglia become activated when getting into contact with certain microbial RNA/DNA 
motifs, cell walls, envelope or surface structures such as lipopolysaccharide (33), a cell 
wall constituent of Gram-negative bacteria. Microglial cells express numerous PRRs, 
which serve in immune defense by detecting these motifs. The innate immune system 
replies not only to exogenous but also to endogenous threats. Microglia sense danger 
associated molecular pattern (DAMP) indicating disorder in host tissues like damaged 
or mutated cells. They then produce and regulate the release of cytokines and 
chemokines that trigger an inflammatory reaction or attract and activate peripheral 
immune cells (58). However, microglia are not only screening for pathogens. There is 
much evidence that they also play a crucial role in tissue repair processes in the brain 
(55). Microglia cells, like other macrophages, reveal a remarkable functional diversity. 
Their reactions, or reactive phenotypes, depend on the challenging stimulus, the 
situational context as well as the modulating impact of their environment. Besides 
others, two very contrary kinds of activation have to be considered in particular. 
Classical or M1 activation is associated with interferon-γ (IFN) and/or microbial agent, 
for example LPS driven inflammatory reactions that are often also cytotoxic. The 
alternative or M2 activation of microglia is strongly related to IL-4 and -13 mediated 
processes that decrease inflammation and support tissue repair and regeneration (59). 
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These two stages represent the extreme forms of this kind of activation and exhibit a 
variety of sub-forms in between. 
In their IL-4 influenced activated form, alternatively activated microglia express 
increased levels of surface structures for cell-cell and cell-matrix interactions, such as 
MHC molecules I and II. Furthermore, they interact with other CNS-resident cells, 
including neurons, astrocytes, oligodendrocytes, endothelial cells as well as with 
immune cell populations, ranging from neutrophils to T and B lymphocytes (55). These 
cell-cell communications are essential for the support of neurogenesis and 
neuroprotection (55). In this regard, microglia themselves can orchestrate and become 
instructed by virtually all of the above cell types. Cellular communication is thereby, not 
exclusively but essentially, built on the exchange of cytokines and chemokines (55). 
The understanding of signals and mechanisms which initiate, guide and limit microglial 
activation and activities are gathering more and more attention as these cells seem to 
be at a key position to maintain CNS health and function.  
 
1.2.3 Microglial cells in pathogenesis   
Besides protecting the CNS against invading microorganisms and maintaining its 
homeostasis microglia are also involved in a series of diseases. A substantial part of 
the pathogenic processes is linked to neurodegeneration due to miss-regulated 
activation of microglia. Multiple sclerosis and Alzheimer`s disease but also bacterial 
and viral infections (60, 61) are among the most prominent cases of this phenomenon. 
The damage done to the neural structures is often due to the unbalanced release of 
pro-inflammatory cytokines like TNF-α, reactive oxygen species (ROS) or nitrate oxide 
(NO) (62). The consequences are among others loss of neuronal structures or 
demyelination of nerve fibers (63). 
Another important finding regarding neuropathology and inflammation is the 
development of glioma. Microglia have been shown to be substantially involved in 
growth and progression of this kind of cancer (64). Microglia and invading 
macrophages are the largest fraction of the inflammatory environment that is 
surrounding the glioma cells. More than 30% of the total tumor mass is finally created 
by tumor infiltrating microglia and macrophages (64). However, instead of initiating 
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cytotoxic anti-glioma actions the microglia/macrophages get polarized towards a M2 
phenotype, which is supporting cell proliferation and therefore tumor progression (65). 
The role of the Siglec receptor family within the field of neuroinflammation and 
degeneration is not fully understood yet. However, there is increasing evidence that 
they could be important contributors to these processes.   
 
1.3. Aim of the study 
Depending on their structure Siglec receptors can modulate pro- or anti-inflammatory 
signaling. The aim of the project is to investigate the role of Siglecs on microglia in an 
inflammatory environment. As model receptors, the ITAM linked Siglec-H and the ITIM 
linked Siglec-11 were chosen. The regulation of both receptors under different kinds of 
stimulation as well as their involvement in essential inflammatory processes like 
phagocytosis or modulation of cytokines will be investigated. While there is no binding 
partner for Siglec-H known so far Siglec-11 recognizes α2-8 linked oligosialic acids, 
preferentially consisting of three monomers. Therefore, Siglec-11 stimulation will be 
used in cell culture and animal systems. The therapeutic potential of both Siglecs will 
be investigated with respect to pathological processes linked to neuroinflammation.  
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2. Material and Methods  
 
2.1 Materials 
2.1.1 Buffers  
10X (0.125M) Phosphate buffered saline (PBS), pH 7.3 
Component Concentration Company 
NaH2PO4*H2O 
NaH2PO4*7H2O 
NaCl 
ddH2O 
0.007 M 
0.034 M 
0.6 M 
up to 1 liter 
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 
10X Tris-borate-EDTA (TBE) buffer 
Component Concentration Company 
Tris-Base 
Boric Acid  
EDTA 
ddH2O 
1.78 M 
1.78 M 
0.04 M 
up to 2 liter 
Roth, Germany 
Sigma, Germany 
Roth, Germany 
Roth, Germany 
 
PBS-Tween-20 (PBST) 
Component Concentration Company 
Tween-20 
PBS (1x) 
500 µl 
up to 1 liter 
Sigma, Germany 
 
 
Arsenite buffer 
Component Concentration Company 
Sodium-arsenite 
HCl 
2 % 
0,5 N 
Sigma, Germany 
Roth, Germany 
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Thiobarbituric acid buffer 
Component Concentrations Company 
2-Thiobarbituric acid 
(adjusted to pH9 ) 
ddH2O 
0,1 M 
 
100 ml 
Sigma, Germany 
 
Roth, Germany 
 
Acid butanol 
Component Concentration Company 
Butan-1-ol 
HCl 
100 ml 
12 N (5% (v/v)) 
Sigma, Germany 
Roth, Germany 
 
Wash buffer (Fusion protein purification) 
Component Concentration Company 
NaH2PO4*H2O (pH 7) 
ddH2O 
20 mM  
up to 1 liter 
Roth, Germany 
Roth, Germany 
 
Elution buffer (Fusion protein purification) 
Component Concentration Company 
HCl (pH 2.7) 
Glycin 
 
0.1 M (up to 1 liter) 
Roth, Germany 
Roth, Germany 
 
Storage buffer (Fusion protein purification) 
Component Concentration Company 
TRIS-HCl (pH 9) 
ddH2O 
1 M 
up to 1 liter 
Roth, Germany 
Roth, Germany 
 
Borane buffer (BrdU) 
Component Concentration Company 
Borane 
ddH2O 
0.1 M 
up to 1 liter 
Roth, Germany 
Roth, Germany 
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2.1.2 Solutions and reaction mix 
 
4% Paraformaldehyde (PFA), pH 7.3 
Component Amount Company 
PFA 
NaOH (1 M) 
PBS (10x) 
ddH2O 
20 g 
30 ml 
50 ml 
up to 1 liter 
Roth, Germany 
Sigma, Germany 
Roth, Germany 
Roth, Germany 
 
Reverse transcription mix 
Component Amount Company 
Total RNA 
Hexanucleotide Mix (10X) 
dNTP mix (10 mM) 
DTT mix (10 mM) 
5X RT 1st Strand Buffer 
RT enzyme (200 U/ml) 
ddH2O 
5 µg 
1 µl 
1 µl 
2 µl 
4 µl 
1 µl 
up to 20 µl 
 
Roche, Germany 
Sigma, Germany 
Invitrogen, Germany 
Invitrogen, Germany 
Invitrogen, Germany 
Roth, Germany 
 
RT-PCR reaction mix (50 µl) 
Component Amount Company 
cDNA (200 ng/µl)  
Buffer (10X)  
dNTP mix (10 mM) 
Primer mix (10 pmol/µl)  
Taq polymerase (5 U/l) 
ddH2O 
5 µl 
5 µl 
2 µl 
2 µl 
0.2 µl 
33.8 µl 
 
Roche, Germany 
Sigma, Germany 
MWG, Germany 
Roche, Germany 
Roth, Germany 
 
qRT-PCR reaction mix (25 µl) 
Component Amount Company 
cDNA (200ng/µl)  
Syber Green Master Mix 
1 µl 
12.5 µl 
 
Invitrogen, Germany 
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Primer mix (10 pmol/µl)  
ddH2O 
2 µl 
9.5 µl 
MWG, Germany 
Roth, Germany 
 
Polyacrylamide gel 
Component Amount Company 
Acrylamide 
5xTBE buffer 
APS 
Temed 
ddH2O 
12 ml 
8 ml 
400 µl 
40 µl 
20 ml 
Roth, Germany  
Roth, Germany 
Roth, Germany 
Roth, Germany 
Roth, Germany 
 
1% Agarose gel 
Component Amount Company 
Tris-Base 
Ethidium Bromide 
TBE (1x) 
0.5 g 
5 µl 
50 ml 
Biozym, Germany 
Roth, Germany 
 
2.1.3 Cell culture media and reagents 
 
Basal cell culture medium (for primary microglia) 
Component Concentration Company 
BME  
Fetal bovine serum  
L-glutamine  
D-glucose (45 %) 
Penicillin/Streptomycin (100X) 
500 ml 
10 % 
1 % 
1 % 
1 % 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
Sigma, Germany 
Gibco, Germany 
 
N2 cell culture medium (for iPSdM and ESdM) 
Component Concentration Company 
DMEM/F-12 
N2 medium 
500 ml 
5 ml 
Gibco, Germany 
Gibco, Germany 
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Penicillin/Streptomycin (100X) 
L-glutamine 
D-Glucose (45 %) 
1 % 
1 mM 
1.7 ml 
Gibco, Germany 
Gibco, Germany 
Sigma, Germany 
 
DMEM cell culture medium (for HEK 293 t/ft) 
Component Concentration Company 
DMEM high glucose 
Fetal calf serum 
Penicillin/Streptomycin (100X) 
L-glutamine 
Na-pyruvate 
Non-essential amino acids 
500 ml 
10 % 
1 % 
1 % 
4 mM 
0.1 mM 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
 
Advanced DMEM cell culture medium (for transfection) 
Component Concentration Company 
Advanced DMEM  
Fetal calf serum 
Penicillin/Streptomycin (100X) 
L-glutamine 
500 ml 
3 % 
1 % 
1 % 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
 
DMEM cell culture medium (for glioma cells) 
Component Concentration Company 
DMEM F/12 
Fetal calf serum 
Penicillin/Streptomycin (100X) 
500 ml 
10 % 
1 %  
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
 
RPMI cell culture medium (for THP-1 cells) 
Component Concentration Company 
RPMI 
Fetal calf serum 
Penicillin/Streptomycin (100X) 
Pyruvate 
500 ml 
10 % 
1 % 
1 % 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
Gibco, Germany 
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Other reagents 
10x4 ligase 
Bgl II 
Chloroquine diphosphate salt 
DNA ladder 
EcoRV 
Hexamer random primers 
Latex Beads (PE) 
Latex Beads (FITC) 
Lipofectamine 2000 reagent 
LPS 
 
Mouse Interferon-alpha 
Mouse Interferon-Gamma 
Mouse TNF-alpha 
MVP Total RNA, human brain 
N-Acetylneuraminic Acid 
Polyethylenglycol 6000 
Polysialic acid 
 
Puromycin 
Phorbol 12-myristate 13-acetate 
Stains all solution 
Trypsin-EDTA (0,025%) 
Zeocin antibiotic 
Roche Diagnostics, Germany 
Roche Diagnostics, Germany 
Sigma, Germany 
Invitrogen, Germany 
Roche Diagnostics, Germany 
Roche Diagnostics, Germany 
Polyscience Inc., Germany 
Polyscience Inc., Germany 
Invitrogen, Germany 
Roche, Germany 
Enzo, Germany 
Hycult Biotech, Netherlands 
R&D Systems, Germany 
R&D Systems, Germany 
Agilent Technologies 
Nacalai Tesque inc, Japan 
Roth GmbH, Germany 
Lipoxen, UK 
Carbosynth, UK 
PAA, Germany 
PAA, Germany 
Sigma, Germany 
Gibco, Germany 
Roth GmbH, Germany 
 
2.1.4 Cells and animals 
 
Cell lines 
Cell line Company 
293 FT HEK cells Invitrogen, Germany 
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Chinese ovarian hamster cells 
E.coli Top10 
Embryonic stem cell derived microglia 
(ESdM) 
GL261 glioma cells 
 
Induced pluripotent stem cell derived  
microglia (iPSdM) 
Primary mouse derived microglia 
SMA glioma cells 
 
THP-1 
Invitrogen, Germany 
Invitrogen, Germany 
Generated by our lab 
 
Provided by Prof. Herrlinger/Dr. Glas, 
University of Bonn 
Generated by our lab 
 
Obtained from C57/Bl6 newborns  
Provided by Prof. Herrlinger/Dr. Glas, 
University of Bonn 
ATCC TIB-202, USA 
Animals 
Mouse strain Company 
C57/Bl6/6J mice 
B6D2 F1/C57/Bl6/6J Siglec-11 transgenic 
mice 
Charles River Laboratories, Germany  
University of Bonn, Germany 
 
2.1.5 Antibodies  
 
Primary antibodies and isotype controls 
Antibody  Host Reactivity Conj. Company 
Anti-BrdU 
CD16/32 (Fc block) 
Fc detection 
IgG2 b κ Isotype control 
IgG2 Isotype control 
Siglec-H 
Siglec-11 
Siglec-11 4c4 
mouse 
rat 
rat 
rat 
goat 
rat 
goat 
mouse 
 
mouse 
mouse 
/ 
/ 
mouse 
human 
human 
 
 
FITC 
biotin 
biotin 
biotin 
biotin 
BD Systems, USA 
BD Pharmingen, Germany 
BD Pharmingen, Germany 
BD Pharmingen, Germany 
Abcam, Germany 
Hycult biotech, Germany 
R&D, Germany  
Prof A. Varki, USA 
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Secondary antibodies 
Antibody  Host Reactivity Conj. Company 
PE 
IgG 
IgG 
/ 
rat 
goat 
mouse 
mouse 
mouse 
streptavidin 
Cy3 
Alexa 488 
BD Pharmingen,  
Jackson, USA 
Jackson, USA 
 
2.1.6 Primer 
 
qRT and RT-PCR (all purchased from MWG, Germany) 
Gene Orientation Sequence 
Human GAPDH (qRT) 
 
Human TNF-α (qRT) 
 
Mouse GAPDH 
(RT/qRT) 
Mouse IL-1 β (qRT) 
 
Mouse TNF-α (qRT) 
 
Siglec-H (RT/qRT) 
 
Siglec-H fusion protein 
(RT) 
 
 
Siglec-11 I (RT) 
 
Siglec-11 genotyping 
 
Siglec-11 II (qRT/RT) 
forward 
reverse 
forward 
reverse 
forward 
reverse 
forward 
reverse 
forward 
reverse 
forward 
reverse 
forward 
 
reverse 
 
forward 
reverse 
forward 
reverse 
forward 
5’- CTGCACCACCAACTGCTTAG-3’ 
5’- TTCAGCTCAGGGATGACCTT-3’ 
5’- GACAAGCCTGTAGCCCATGT-3’ 
5’- AGGACCTGGGAGTAGATGAGG-3’ 
5’- ACAACTTTGGCATTGTGGAA-3’ 
5’- GATGCAGGGATGATGTTCTG-3’ 
5’- CTTCCTTGTGCAAGTGTCTG -3 
5’- CAGGTCATTCTCATCACTGTC -3’ 
5’- TCTTCTCATTCCTGCTTGTGG-3’ 
5’- AGGGTCTGGGCCATAGAACT-3’ 
5’-GTGACAGACCTCACTCACAGCCC-3’ 
5’-GGTCGTGGGGCCCAGGGATA-3’ 
5’-ATAAGATCTGGTGACATTGAGCTG 
GATAG-3’ 
5’-CATAAGGTTCTGGAAACTGCTTTA 
TTCTC-3’ 
5’- ACAGGACAGTCCTGGAAAACCT-3’ 
5’- AGGCAGGAACAGAAAGCGAGCAG -3’ 
5’- GGAGATGTCAGGGATGGTTC-3’ 
5’- AGCAGCGTATCCACATAGCGT-3’ 
5’-CACTGGAAGCTGGAGCATGG-3’ 
Material and Methods 
 
 
 27 
reverse 5’-ATTCATGCTGGTGACCCTGG-3’ 
 
2.1.7. Consumables, equipment and software 
 
Consumables 
6-well culture plates  
15 ml tubes  
50 ml tubes  
5 ml, 10 ml, 25 ml pipettes  
75 ml, 175 ml culture flasks  
5 ml polystyrene round-bottom tubes 
3 cm, 5 cm, 10 cm culture dishes  
500 µl, 1000 µl plastic tubes  
PCR tubes  
10 µl, 100 µl, 1000 µl tips  
5 ml, 10 ml syringes + needles  
Filters (0.45 µm, 0.2 µm pore)  
VWR International, Germany 
VWR International, Germany 
Sarstedt, Germany 
Sarstedt, Germany 
Sarstedt, Germany 
BD Falcon, Germany 
Sarstedt, Germany 
Eppendorf, Germany 
Biozym Diagnostics, Germany 
Eppendorf, Germany 
Braun, Germany 
Sarstedt, Germany 
 
Equipment 
ABI 5700 Sequence Detection System  
Centrifuges  
 
Electrophoresis 
Mastercycler realplex 4 
Flow cytometer   
NanoDrop ND-1000 spectrophotometer 
Envision Multiplate Reader 
HRP sepharose anion-exchange column 
(53ml) 
PerkinElmer, USA 
Megafuge, 1.OR. Heraeus, Germany      
Biofuge Fresco, Heraeus, Germany   
Peqlab, Germany 
Eppendorf, Germany 
FACS Calibur, BD Bioscience, Germany 
Peqlab, Germany 
Perkin Elmer, USA 
GE Healthcare, Germany 
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Software 
Cellquest Pro 
CorelDRAW  
Openlab4.0.1  
EndNote X  
FlowJo 6.4.7 
ImageJ 1.44p 
Microsoft Office 2004 
Realplex 4 
Wolframalpha  
BD Biosciences, USA 
Graphics Suite 11, Germany 
Improvision, Germany 
Thomson ISI ResearchSoft, USA 
Tree Star, USA 
National Institute of Health, USA 
Microsoft, USA 
Eppendorf, Germany 
Wolfram Research, USA 
 
2.1.8 Kits 
Bradford protein assay 
Colorimetric (MTT) Kit for cell survival 
and proliferation 
RNeasy Mini Kit 
RNeasy Mini Kit for lipid tissue  
RNAse free DNAse Kit 
QIAprep Plasmid Miniprep  
Endofree Plasmid Maxiprep 
Red Extract-N-Amp Tissue PCR Kit 
Sigma, Germany 
Millipore, Germany 
 
Qiagen, Germany  
Qiagen, Germany  
Qiagen, Germany  
Qiagen, Germany  
Qiagen, Germany  
Qiagen, Germany 
 
2.2 Methods 
2.2.1 Cell culture 
Primary microglia were prepared from brain tissue of newborn (P3-P4) C57Bl/6 mice. 
In brief, the pubs were decapitated and scull bone and meninges were removed. Brain 
tissue was dissociated mechanically by trituration. Cells from the hippocampus and 
cortex regions were taken for culture in 75 ml flasks. After 14-21 days in basal medium 
the cells formed a confluent layer of glial cells. For harvesting the flasks were shaken 
on a rotary shaker for 3 hours at 350 rpm and detached microglia were plated onto 
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poly-L-lysine (PLL)-coated cell culture dishes. All cell lines used were kept on 10 or 15 
cm culture dishes under normal conditions at 37 °C and 5 % CO2. Cell culture media 
were utilized as indicated in chapter 2.1.3. Splitting was done via trypsin treatment for 
5 minutes subsequent centrifugation and seeding on new culture dishes. 
The human monocyte line THP-1 was cultured in 75 ml cell culture flasks. For 
differentiation of human tissue macrophages the line was cultured for 3 hours in the 
normal cell culture medium containing 0.5 µM phorbol 12-myristate 13-acetate (PMA). 
Medium was changed into PMA free culture medium and the cells were cultured for 24 
hours to allow differentiation into mature macrophages. 
 
2.2.2 RT- and quantitative RT-PCR 
RNA was isolated from cultured cells or tissue samples by using the RNeasy Mini and 
RNeasy for lipid tissue Kit. Reverse transcription of the RNA (5 µg/sample) was 
performed using Super Script III reverse transcriptase and hexamere random primers. 
The concentration of the samples was determined via NanoDrop spectrophotometer 
and diluted to 200 ng/µl past transformation into cDNA. Siglec-11 genotyping of the 
transgenic mice via PCR was done over 30 cycles (initial denaturation 95 °C for 3 
minutes, denaturation 95 °C for 30 seconds, annealing 60 °C for 40 seconds, 
extension 72 °C for 50 seconds, final extension 72°C for 10 minutes). The other RT-
PCR products were amplified for 35 cycles but Siglec-H (initial denaturation 94 °C for 
10 minutes, denaturation 94 °C for 90 seconds, annealing 65,5 °C for 60 seconds, 
extension 72 °C for 60 seconds, final extension 72 °C for 10 minutes), Siglec-11 I 
(initial denaturation 94 °C for 2 minutes, denaturation 94 °C for 90 seconds, annealing 
62.5 °C for 60 seconds, extension 68 °C for 60 seconds, final extension 68 °C for 10 
minutes) and Siglec II (initial denaturation 94 °C for 5 minutes, denaturation 94 °C for 
60 seconds, annealing 60 °C for 60 seconds, extension 72 °C for 60 seconds, final 
extension 72°C for 10 minutes ) required different conditions. All qRT-PCR reactions 
were running for 40 cycles if not indicated otherwise (initial denaturation 95 °C for 8.30 
minutes, denaturation 95 °C for 15 seconds, annealing 60 °C for 30 seconds, 
extension 72 °C for 30 seconds, stepwise to 95 °C over 20 minutes). Ethidium bromide 
agarose gels of 1 % were used for visualization of PCR products.  
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Gene transcripts of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were applied as internal control. Quantitative RT-PCR with 
specific oligonucleotides was performed with SYBR Green PCR Master Mix using the 
ABI 5700 Sequence Detection System and amplification protocol for the ABI 5700 
Sequence Detection System. Amplification specificity was confirmed by the analysis of 
the melting curves. Results were analyzed with the ABI 5700 Sequence Detection 
System version 1.3. Oligonucleotides used for PCR amplification are listed in chapter 
2.1.6. The δδCT method with GAPDH as internal standard was performed for real-time 
PCR quantification 
 
2.2.3 Bromo Deoxyuridine (BrdU) cell proliferation assay  
Cell proliferation was assayed via detection of BrdU incorporation into the cells during 
mitosis. Microglia cells were transduced with a green fluorescent protein (GFP) 
expressing construct (kindly provided by the groop of Prof. Oliver Brüstle) prior to the 
experiments. In brief, the two glioma cell lines SMA560 and GL261 were mono- or co-
cultured with IFN-γ activated GFP-expressing microglia (104 cells from each type) on 
four-well chamber slides for 24 hours. BrdU was added to glioma cells in a 
concentration of 10 µM. After time intervals of 0.5, 1, and 2 hours the cells were fixed 
with 4 % PFA and washed with PBS. Membrane permeabilization was achieved by 30 
minutes incubation with 0.5 % Triton X-100 (Sigma-Aldrich) and subsequent DNA 
denaturation by incubation in 2 M HCl for 10 minutes. For the neutralization of the acid, 
0.1 M borane buffer was used for another 10 minutes. Extensive washing with PBS 
was performed in-between each of the respective steps. Following 15 minutes of 
blocking (5 % FCS/0.1 % Triton X-100/ PBS) a monoclonal mouse anti-BrdU antibody 
(3 % FCS/0.1 % Triton X-100/ PBS) was added. The samples were washed with PBS 
and a Cy3-conjugated rat-anti-mouse secondary antibody was added (3 % FCS/0.1 % 
Triton X-100/ PBS). Before mounting, the nuclei were stained for 2 minutes with 4',6-
diamidino-2-phenylindole (DAPI) in a dilution of 1:10000. Subsequently, analysis by 
confocal microscopy was performed. For quantification at least three pictures of each 
condition per experiment were taken. Using ImageJ software the ratio of BrdU-positive 
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plus GFP-negative glioma cells to the total number of GFP-negative glioma cells in 
mono- and co-culture was determined. 
 
2.2.4 Generation of the Siglec-H fusion protein 
For the creation of the Siglec-H fc fusion protein a commercially obtained fc part 
containing pFUSE-hIgG1e3-Fc2 (IL2ss) backbone plasmid was used. The extracellular 
part of the Siglec-H receptor was purified via RT-PCR from a mouse 
IRAVp968D06168D full-length cDNA clone (ImaGenes). For the assembling the 
restriction enzymes Bgl II and EcoRV (1 hour at 37 °C) and 10x T4 ligase (16 °C over 
night) were used according to the manufacturers instructions. 100 to 500 ng of the 
plasmid were put via transformation into competent cells (E.coli Top10). The cells were 
plated on antibiotic resistant culture dishes and incubated at 37 °C over night. Colonies 
were picked and grown in antibiotic (Zeocin) containing LB-medium. Glycerol stocks 
were created from the successfully grown cultures.  
 
2.2.5 Production of viral particles and the Siglec-H fusion protein 
The plasmids for the murine Siglec-H knock-down (TRCN0000068083, Target 
sequence: 5’-GCCCAAATTAACATTAGAGAA-3’) were a kind gift from Prof. Veit 
Hornung from the University of Bonn. A pLKO.1 puro non targeting control vector 
(Sigma, Catalog Nr. SHC002) was used as control.  
Plasmids were transfected into FT293 HEK cells via a CaCl2 based protocol. In brief, 
6.5 x 106 cells were plated on 15 cm cell culture dishes. Regular cell culture medium 
was changed directly before the procedure to MEF medium with 5 % FCS. The vector 
plasmid (25 µg) was put together with 37.5 µg of packaging plasmids (25 µg 3rd 
generation: pMDL gag/pol PRE + 12.5 µg pRSV-Rev) and 15 µg of envelope plasmid. 
1.125 ml of sterile H2O and 125 µl of CaCl2 (2.5 M) was added to the plasmids and 
incubated for 3 minutes. 1.25 ml of 2x HBS was added and the solution was mixed 
properly. Afterwards, an incubation period of 25 minutes was given. Finally, the 
solution was added to the HEK 293 FT cells and over night incubation at 37 °C and 5 
% CO2 was performed. Next morning the medium was changed and the viral particles 
Material and Methods 
 
 
 32 
were harvested after 24 and 48 hours (with another medium change after 24 hours in 
between). The viral particle-containing medium was mixed 1:1 with the regular culture 
medium and added for 72 hours in total to the microglial cells. Positive selection of the 
transduced cells was achieved by adding Puromycin (25 µg/ml, PAA) to the cells after 
the medium was changed. The efficiency of the respective treatment was determined 
via flow cytometry.  
Plasmids for lentiviral knock-down of human Siglec11 (shRNASig11: 
TRCN0000062841, Open Biosystems) were obtained from a knock-down library in a 
human pLKO.1 lentiviral shRNA target gene set backbone (Open Biosystems). A 
pLenti 6.2/V5_DEST Gateway Vector (Life technologies) without target gene served as 
control vector. Here, for production of lentiviral particles a different protocol than for the 
Siglec-H knock-down was used. PLL coated HEK 293 FT cells were transfected with 
the targeting and packaging plasmids pMD2.G and psPAX2. Two hours before 
transfection the cell culture medium was changed from regular MEF to an advanced 
MEF medium. For transfection of an 80 % confluent 10 cm culture dish lentivector 
(18.5 µg), helper (9.25 µg) and envelope plasmid (9.25 µg) were mixed together with 
61.5 µl 2.5 M CaCl2 and filled up with distilled water to 600 µl total volumes. After 5 
minutes of incubation, 600 µl of 2xHBSS was added. 15 minutes of incubation was 
given subsequently to allow formation of complexes. In the meantime 25 µM/ml 
chloroquine was added to the cells to increase transfection efficiency. Medium was 
changed 5 hours post-transfection back to the regular MEF medium to remove the 
chloroquine and a second time, 12 hours later. Supernatant was then collected 48 and 
72 hours after transfection. For precipitation the viral particle containing supernatant 
was incubated for 1.5 hours with 8.5 % Polyethylenglycol, 0.3 M NaCl and PBS at 4 
°C. Subsequently the solution was centrifuged with 4500 g at 4 °C for at least 30 
minutes. The viral particle-containing pellet was resuspended in 1 ml of 1xPBS and 
added to the target cells. After 72 hours of incubation transduced cells were selected 
by addition of 1 µg/ml puromycin. The knock-down efficiency was determined by qRT-
PCR and flow cytometry. 
The Siglec-H fc fusion protein plasmid was transfected into chinese ovarian hamster 
cells in a similar way to the plasmids coding for viral particles except that a low IgG 
FCS containing cell culture medium was used. The protein containing supernatant was 
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directly taken for purification via a protein-G sepharose column designed to detect the 
fc tag of the protein. The purification procedure was carried out according to the 
manufacturers instructions. The concentration of the elution fractions was determined 
via a Bradford protein assay. 50 µl of fraction was diluted with reagent solution in a 
ratio of 1:16 and incubated for 10 minutes at room temperature. To determine the 
concentration, the solution was measured at a wavelength of 465 nm with a reference 
wavelength of 595 nm against a standard. The Siglec-H fusion protein was stored at -
80 °C. 
 
2.2.6 Bead phagocytosis assay 
For investigation of phagocytosis activity microglial cells and macrophages were plated 
on 6 well plates in a concentration of 2,5 x 105 cells per well. The cells were stimulated 
depending on the experiment 24 hours prior to the addition of the beads if not indicated 
otherwise. For the Siglec-H related experiments FITC fluorescent streptavidin coated 
beads were pre-incubated with biotin linked primary Siglec-H or Isotype control 
antibodies (500 ng/ml) for 1 hour at 4 °C to increase the uptake specificity. Incubation 
with the beads (1 µl beads/ml medium) was performed for 1h under regular cell culture 
conditions (37 °C, 5 % CO2). For analysis the media was removed and cells were 
treated for 1-2 minutes with trypsin (0.025 %) in order to get rid of beads sticking to the 
surface of the microglia. Afterwards the cells were washed 3x with PBS before being 
detached mechanically. Fluorescence intensity of 3 x 104 cells per sample was 
measured via the FL-1 channel by flow cytometry. 
For the Siglec-11 related phagocytosis experiments PE labeled latex beads were used 
in a concentration of 1 µl beads/ml medium. The cells were stimulated for 24 hours 
and beads were added for 1 hour. All steps were performed under regular cell culture 
conditions (37 °C, 5 % CO2). For analysis fluorescence intensity of 3 x 104 cells per 
sample was measured via the FL-2 channel by flow cytometry. 
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2.2.7 Flow cytometry 
The mouse microglia cells (ESdM and primary microglia) were harvested mechanically 
and diluted to a concentration of 1 x 106 cells per ml. The samples were washed 3 
times with PBS via centrifugation. A rat anti-mouse CD16/CD32 fc blocking antibody 
(0.5 mg/ml, 1:100 dilution) was added 5 minutes prior to staining with the biotin labeled 
Siglec-H primary antibody. The incubation time for the primary antibodies was 1 hour 
at 4 °C. Streptavidin linked PE serving as secondary antibody was added for 30 
minutes at 4 °C (0.5 mg/ml, 1:200 dilution). For analysis 3x104 cells per sample were 
measured via a FACS Calibur flow cytometer. Primary microglia derived from the 
Siglec-11 transgenic mice were stained with a non-commercial 4c4 Siglec-11 antibody 
on ice (1:10 dilution). The secondary antibody was an alexa 488-conjugated goat IgG2 
directed against mouse (1:200 dilution) that was added for 30 minutes on ice as well. 
Human microglia cells were immunostained with biotin-conjugated Siglec-11 specific 
antibodies followed by streptavidin-PE. An irrelevant isotype antibody was used as 
control. Cells were analyzed by flow cytometry like the mouse microglia. The THP-1 
cells were stained the same way like the microglia. The fusion protein was taken 
instead of the primary antibody (25 µg/ml) and a FITC linked antibody (0.5 mg/ml, 
1:100 dilution) directed against the fc-tag of the protein was used for detection. The 
incubation time for both steps was 1 hour at 4 °C.  
 
2.2.8 Purification of polysialic acid (PSA) 
As a preparative step the samples were heated at 65 °C for 90 minutes to break the 
long chained PSA down into smaller peaces. For separation of the fragments PSA 
(250 mg) was subjected to a 53 ml HRP sepharose anion-exchange column and 
separated via a high performance liquid chromatography (HPLC) system. The flow-
through was collected in 80 fractions with a respective volume of 8 ml. To get rid of 
buffer residues the samples were lyophilized and the yield solved in PBS or distilled 
water. To increase the sample concentration 3-4 fractions of interest were pooled 
together. Samples of the fractions were loaded on a polyacrylamide gel separated for 4 
hours and stained with stains all solution for size determination. Using the 
Thiobarbituric acid based method published by Aminoff et al. in 1961 (66) the 
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quantification of the fractions was performed. Commercially obtained Neu5Ac  served 
as standard to determine the respective concentrations. The standard and test 
samples are treated with 25 µl of 25 mM periodic acid in 0.125 M H2SO4 and incubated 
at 37 °C for 30 minutes. Past the incubation step 20 µl of 2 % sodium arsenite solution 
(in 0.5 N HCl) was added to each sample in order to reduce the excess of periodate. 
After 2 minutes at room temperature 200 µl of 2-thiobarbituric acid (0.1 M, pH 9) was 
given to the samples. Subsequently, a heating step (7.5 minutes at 99 °C) was 
performed that caused the formation of a red colored complex. The solution was 
cooled on ice for 5 minutes and afterwards shaken with 500 µl/sample acid butanol 
(butan-1-ol plus 5 % of 12 N HCl). A rapid centrifugation supported the separation of 
the phases. The intensity of the colorful upper phase was measured via spectrometer 
at 549 nm. Quantification was afterwards performed based on the NANA standard. 
Past the quantification the PSA samples were diluted to a stock concentration of 1 
mg/ml and sterile filtered (0,2 µm).  
 
2.2.9 Size determination of PSA 
To determine the size of the purified PSA polyacrylamide gel based chromatography 
was performed. The gel-based analysis was done via native 18 % and 20 % Tris-
Glycine polyacrylamide gels. The running time of the gels was 2.5 hours at 120 V for 
the 18 % gels and 3.5 hours for the 20 % gels. Subsequently, the gels were stained via 
a protocol from Goldberg and Warner (67) for at least 2 hours at room temperature 
with stains-all solution (30 mM Tris, 25 % isopropanol, 7.5 % formamide and 0.025 % 
(w/v) stains all at a pH of 8.8). Afterwards, the gel was washed 3 to 4 times for 10 
minutes with 25 % isopropanol to clear the background.  
 
2.3.1 Cell proliferation and metabolic activity assay  
Metabolic activity was assayed via a colorimetric (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Millipore). The mitochondria mediated 
cleavage of MTT by cells leads to the formation of formazan crystals. Cells (104 per 
well) were seeded on a 96 well plate in a volume of 100 µl/well and treated for 24 
hours with different concentrations of distinct sialic acid chain lengths at standard 
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culture conditions (5 % CO2, 37 °C). After 20 hours of stimulation with different kinds of 
sialic acids 10 µl of MTT (stock 5 mg/ml) were added and cells were cultured for 
another 4 hours. To dissolve the formazan crystals 100 µl of isopropanol with 0.04 N 
HCl were added to each well. The light absorbance of the purple formazan dye was 
determined by a spectrophotometer at a wavelength of 570 nm with a reference 
wavelength of 630 nm. Microglia that were plated and stimulated under exact identical 
conditions were detached by trypsin treatment and counted via a Neubauer cell 
chamber. Measured absorbance values were divided through the number of cells per 
well to determine the turnover per single cell. All values were compared to 
unstimulated control cells to receive the relative changes of cell proliferation and 
metabolic activity. 
 
2.3.2 Experimental animal models 
A Siglec-11 transgenic mouse line generated by Dr. Yiner Wang (107) was used for 
the in vivo experiments. For the investigation of Siglec-11 in inflammation a LPS 
induced model of systemic inflammation was chosen. The genotyping of the Siglec-11 
mice was done as described in chapter 2.2.2. In case of the LPS injection model 
C57/Bl6/6J mice or C57/Bl6/6J Siglec-11 transgenic mice were injected with either 4x 
1 µg LPS/g body weight or PBS for 5 days. PSA-20 was always injected in a 
concentration of 4x 1 µg/g body weight parallel to LPS or PBS. 
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3. Results 
 
3.1 Siglec-H in neuroinflammation 
3.1.1 Detection of Siglec-H transcripts in microglia 
Siglec-H was initially found to be present on PDCs. In order to confirm that Siglec-H 
was expressed not only by PDCs but also on microglial cells RT-PCR and qRT-PCR 
was performed. Therefore, primary microglia and ESdM a mouse microglia cell line 
were taken for the experiments. PDC rich mouse spleen was used as positive control 
for the PCR experiments. A H2O control was included on a regular basis to all 
experiments as well. 
The Siglec-H receptor is linked to the ITAM associated transmembrane adapter protein 
DAP12 that is capable of transmitting pro-inflammatory signals. To study the Siglec-H 
regulation the microglia were challenged with a line of pro-inflammatory cytokines. IFN-
α, IFN-γ, LPS, or TNF-α were chosen for a 24 hours lasting challenge of the cells. 
Results RT-PCR experiments revealed that Siglec-H is not notably expressed on 
primary microglia or ESdM in an unstimulated state. Treatment with IFN-α, LPS, or 
TNF-α did not have a detectable effect either. However, IFN-γ stimulation led to a 
detectable increase of the Siglec-H transcription (Figure 3.1 A) 
  
A 
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Figure 3.1 Detection of Siglec-H transcripts on microglia: A Detection of Siglec-H transcripts in 
microglia via RT-PCR. Cells were stimulated for 24 hours with IFN-α (1000 U/ml), IFN-γ (100 U/ml), LPS 
(500 ng/ml), or TNF-α (20 ng/ml). The regulation of Siglec-H was compared to an untreated sample 
using GAPDH as internal control. During the RT-PCR experiments only IFN-γ led to increased 
transcription of Siglec-H in the microglia cells. The data represent the outcome of 3 individual 
experiments. B Detection of Siglec-H transcripts in M1 but not M2 polarized microglia via RT-PCR. Cells 
were stimulated for 24 hours with a combination of IFN-γ (100 U/ml) and LPS (500 ng/ml) for M1 and IL-
4 (20 ng/ml) for M2 polarization. The regulation of Siglec-H was compared to an untreated sample using 
GAPDH as internal control. Only the combination of the pro-inflammatory molecules LPS and IFN-γ led 
to a detectable signal. The data represent the outcome of 3 individual experiments. C Quantification of 
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Siglec-H RNA levels in a microglia line via qRT-PCR. Cells were stimulated for 24 hours with IFN-α 
(1000 U/ml), IFN-γ (100 U/ml), LPS (500 ng/ml), and TNF-α (20 ng/ml). The regulation of Siglec-H 
transcripts was compared to an untreated sample using GAPDH as internal control. Via qRT-PCR, only 
stimulation of the cells with IFN-γ led to a statistical relevant change in the expression of Siglec-H. 
Values are given as mean plus SEM with 4 individual experiments. Statistical analysis of the qRT-PCR 
derived data was done by SPSS software. Anova Bonferroni was chosen as test (✶≤p<0.05). Adapted 
and modified from Kopatz et al. 2013. 
 
Furthermore, the regulation of Siglec-H was also investigated in M1 and M2 polarized 
cells. The M1 polarization was achieved via a combination of LPS and IFN-γ while IL-4 
stimulation was chosen for the M2 polarization. Here again only stimulation of the 
microglia cells with IFN-γ in combination with LPS as used for the M1 polarization 
delivered a signal. As expected the treatment with IL-4 was not having any effect 
(Figure 3.1B). A quantification of the ESdM RNA levels via qRT-PCR showed that 
again LPS and TNF-α failed to mediate a noteworthy up-regulation of Siglec-H. In 
contrast, IFN-γ stimulation increased the regulation of Siglec-H to a significant extent 
(20.55+/-6.28 fold, p=0.043). The effect of IFN-α to the cells was found to be not 
significant (Figure 3.1 C). In PDCs the expression of Siglec-H is known to be 
constitutive. The results from the microglia confirm the presence of Siglec-H on RNA 
level. However it is inducible and not constitutive expressed. 
 
3.1.2 Detection of Siglec-H on the cell surface of microglia 
To confirm the presence of Siglec-H not only on the RNA but also on the protein level 
microglia were investigated via flow cytometry. Stimulation with the different pro-
inflammatory cytokines IFN-α, IFN-γ, LPS, or TNF-α was done over a period of 24 
hours. Furthermore, consequences of M1 and M2 polarization with respect to Siglec-H 
regulation were investigated as well. Primary microglia and cells of the microglia cell 
line were studied. The stimulation with IFN-γ revealed a notable increase in Siglec-H 
expression the cell surface of the primary microglia. LPS, IFN-α and TNF-α were not 
showing any positive signal and were comparable to the unstimulated control cells. In 
the microglia line the IFN-γ induced increase in Siglec-H expression was even more 
intense than in the primary microglia.  
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Figure 3.2 Detection of Siglec-H on the cell surface of microglia: A Siglec-H is up-regulated on the 
protein level after IFN-γ and IFN-α treatment. Primary microglia and cells of the microglial line were 
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stimulated with IFN-α (1000 U/ml), IFN-γ (100 U/ml), LPS (500 ng/ml) or TNF-α (20 ng/ml). IFN-γ led to a 
strong increase in Siglec-H protein expression in both types of microglia. IFN-α showed a slight increase 
in the microglia line but not in the primary microglia. The data represent the outcome of 4 individual 
experiments. B Siglec-H is up-regulated on protein level after M1 polarization via IFN-γ/LPS co-
treatment. The data represent the outcome of 3 individual experiments. Adapted and modified from 
Kopatz et al. 2013. 
 
Also a slight increase was mediated by IFN-α however it was no were reaching the 
intensity of the IFN-γ treatment. Furthermore, no effect of the LPS and TNF-α 
stimulation was detected (Figure 4 A). Generally, the findings were in line with those 
obtained from the RT- and qRT-PCR experiments. The results gained after M1 and M2 
stimulation were also following the pattern seen on RNA level. IL-4 was without any 
effect whereas the M1 polarization led to a notable increase of Siglec-H presence on 
both kinds of microglia cells (Figure 4 B). 
 
3.1.3 Lentiviral knock-down of Siglec-H  
To knock-down Siglec-H of microglia a lentiviral mediated transduction of sh-RNA was 
performed. The efficiency of the respective treatments was tested via flow cytometry. 
In accordance with the previous findings no Siglec-H was detected on microglia when 
they were unchallenged or treated with the virus alone. Therefore, a 24 hours 
stimulation interval with IFN-γ was introduced before the determination of the knock-
down efficiency. In parallel to the Siglec-H knock-down, a second group of cells was 
challenged with a control plasmid. Less than 1 % of the untreated control microglia 
showed positive staining for Siglec-H. After IFN-γ treatment nearly 85 % of the control 
microglia were positive for Siglec-H. Virus transduced microglia were presenting 1.2 % 
positive cells without stimulation and 5.86 % positive cells past IFN-γ administration 
(Figure 3.3). 
When comparing IFN-γ treated wild type microglia with the virus treated cells a 90 % 
reduction of Siglec-H on the cell surface was found. Therefore, the cells were found 
suitable for further experimental usage. 
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Figure 3.3 Lentiviral knock-down of Siglec-H: Sh-RNA mediated knock-down of Siglec-H in the 
microglial line. The effect on the protein level was determined via flow cytometry on untreated cells or 
after 24 hours IFN-γ challenge (100 U/ml). The calculated knock-down efficiency was around 90%. The 
data represent the outcome of 3 individual experiments. Adapted and modified from Kopatz et al. 2013. 
 
3.1.5 Microglia specifically engulf Siglec-H 
So far, the role of Siglec-H within the immune system is not well defined. There are 
data that are suggesting a connection of Siglec-H with endo- and phagocytosis (47). 
To follow up this idea, different samples of wild type and sh-RNA transduced cells from 
the microglia line (one plasmid targeting Siglec-H and one control sh-RNA plasmid) 
were prepared and partly pretreated for 24 hours with IFN-γ. Subsequently, the cells 
were incubated for 1 hour with fluorescent latex beads. To distinguish between Siglec-
H mediated and unspecific engulfment the beads were coated with either a Siglec-H 
detecting antibody or an isotype control antibody. The degree of bead uptake was 
determined via flow cytometry.  
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The phagocytosis assay revealed no difference of uptake between Siglec-H coated 
beads (13.47+/-0.59 %) and control beads (13,07+/-0.84 %) without stimulus. The 
engulfment of Siglec-H antibody coated beads in IFN-γ stimulated microglia cells was 
significantly increased (28.77+/-2.25 % p=0,001) compared to the corresponding 
control microglia cells (12.77+/-1.04 %).  
The knock-down of Siglec-H had a notable effect on the IFN-γ pretreated microglia. 
Treatment with sh-Siglec-H reduced the uptake of Siglec-H antibody coated beads in a 
way that no difference was detectable any more between sh-Siglec-H (14.22+/-2.82 
%,) and sh-control treated (12.35+/-2.43 %, p=1.000) microglia. The control sh-RNA 
carrying microglia showed no unspecific knock-down effects. The difference of Siglec-
H bead phagocytosis between the IFN-γ stimulated sh-Siglec-H or control sh-RNA 
microglia and knock-down microglia was found to be significant (p=0.005) as well 
(Figure 3.4 A+B).  
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Results 
 
 
 44 
B 
 
 
Figure 3.4 Microglia especially engulf Siglec-H: A Bead phagocytosis of antibody coated latex beads 
by microglia. Coating of the beads with Siglec-H did not change uptake behavior in untreated cells. IFN-
γ (100 U/ml) stimulated cells showed an increase of Siglec-H coated bead uptake in comparison to 
control beads. Samples treated with sh-RNA were less effective in taking up the Siglec-H coated beads. 
Cells carrying the control sh-RNA revealed the same phagocytosis pattern as the just IFN-γ treated 
cells. B The anti Siglec-H sh-RNA significantly reduced the bead phagocytosis in IFN-γ stimulated 
microglia compared to the wild type and controls sh-RNA samples. Statistical analysis of the 
experiments was performed using SPSS software and Anova Bonferroni as test. The values are given 
as mean plus SEM of 3 individual experiments (✶✶=p≤0.01, ✶✶✶=p≤0.001). Adapted and modified from 
Kopatz et al. 2013. 
 
3.1.6 Glioma cells are recognized by a Siglec-H Fc fusion protein   
So far, no ligand for Siglec-H is known. To investigate whether Siglec-H recognizes 
certain pathological structures on glioma cells, but leaves normal cells unaffected, 
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various cells were incubated with a Siglec-H fusion protein. For this purpose a Siglec-H 
FC fusion protein (linking the extracellular domain of Siglec-H to the Fc part of human 
IgG1) was constructed.  
The two murine glioma cell lines SMA560 and GL261 were compared to control cells.  
As controls murine fibroblast, astrocytes and spleenocytes were used. While the 
control cells showed no notable binding of the Siglec-H Fc fusion protein to structures 
on the cell surface, the Siglec-H Fc fusion protein bound to the two tested glioma cell 
lines (Figure 3.5).  
 
 
 
Figure 3.5 Glioma cells are recognized by a Siglec-H Fc fusion protein: Flow cytometry analysis of 
Siglec-H Fc fusion protein binding capacity. The Siglec-H Fc fusion protein (25 µg/mL) bound to both 
GL261 and SMA560 glioma cells (kindly provided by Prof. Herrlinger and Dr. Glas, University of Bonn), 
but not to astrocytes, splenocytes or fibroblasts derived from normal C57Bl/6 mice. Data were generated 
in collaboration with Dr. Janine Claude and Johannes Ackermann. Representative data out of 3 
independent experiments are shown. Adapted and modified from Kopatz et al. 2013. 
 
3.1.7 No alteration of proliferation speed in glioma cells co-cultured with 
microglia 
Since the Siglec-H receptor bound to certain structures on glioma cells it was 
interesting to test whether a co-culture of glioma cells and activated Siglec-H 
expressing microglia would alter the proliferation rate of the cancer cells. To 
investigate this question a BrdU assay was performed. Therefore, IFN-γ activated 
microglia were co-cultured with SMA560 and GL261 glioma cells for 24 hours. To 
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distinguish the microglia from the glioma cells they were transfected with a GFP 
construct in advance. The co-culture was compared regarding proliferation to glioma 
cells that were cultured alone. Afterwards the percentage of glioma cells that 
incorporated BrdU over a 0.5, 1 or 2 hours time period was determined. No effect of 
activated microglia cells on the glioma cell proliferation rate of SMA560 and GL261 
was observed at any of the tested intervals (Figure 3.6). 
 
 
Figure 3.6 No alteration of proliferation speed in glioma cells co-cultured with microglia: 
Determination of glioma proliferation by incorporation of BrdU after co-cultured with GFP transduced 
microglia. The glioma lines SMA560 and GL261 (kindly provided by Prof. Herrlinger and Dr. Glas, 
University of Bonn) were either cultured alone or co-culture for 24 hours with activated microglia before 
addition of BrdU. Cells were fixed 0.5, 1, or 2 hours after challenge with BrdU. No significant differences 
were detected among the different groups. Data are presented as mean plus SEM of 3 independent 
experiments. Statistical analysis of the experiments was performed using SPSS software and Anova 
Bonferroni as test. Adapted and modified from Kopatz et al. 2013. 
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3.2. Siglec-11 in neuroinflammation 
3.2.1 Detection and regulation of Siglec-11 in human microglia cells  
The expression of Siglec-11 in human microglia was discovered recently (23). To 
confirm its presence in the human microglia cell line (iPSdM-L1) RT-PCR, qRT-PCR 
as well as flow cytometry analysis was performed. For the experiments the cells were 
tested for Siglec-11 without further treatment. For the RT-PCR experiments DNA 
originating from human brain tissue was used as positive control. Transcripts of Siglec-
11 were found to be constitutive expressed by untreated microglial cells (Figure 3.7 A).  
For further investigation the human microglia were stimulated with LPS, TNF-α, IFN-γ 
and IL-4. The Siglec-11 regulation was determined on RNA and protein level using a 
time frame of 24 hours of stimulation. All of the compounds used, up-regulated Siglec-
11 transcription of the human microglia. TNF-α (2.28+/-0.31 fold) and IFN-γ (2.08+/-0.3 
fold) had a significant impact on the gene transcription and protein expression. The 
effect of LPS (1.41+/-0.37 fold) and IL-4 (1.31+/-0.18 fold) treatment on the Siglec-11 
transcription was notably weaker. However, both caused higher Siglec-11 levels then 
the untreated control sample (Figure 3.7 B). 
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Figure 3.7 Detection and regulation of Siglec-11 on human microglia cells: A Determination of 
Siglec-11 transcription on RNA level in cells of the microglia line. GAPDH served as internal control. B 
Regulation of Siglec-11 on RNA level via qRT-PCR in human microglia after stimulation. For 24 hours. 
Cells were treated with IFN-γ (1000U/ml), LPS (1µg/ml) IL-4 (20ng/ml) or TNF-α (20ng/ml). GAPDH 
served as internal control. Siglec-11 transcription is up-regulated under every condition tested. The 
strongest increase in transcription was found under IFN-γ and TNF-α treatment. The values are given as 
mean plus SEM of at least 4 individual experiments. Statistical analysis was done using SPSS software. 
Anova Bonferroni was chosen as test (✶=p≤0.05). C Determination of Siglec-11 regulation on the cell 
surface of microglia via flow cytometry. Cells were stimulated with IFN-γ (1000 U/ml), LPS (1 µg/ml) IL-4 
(20 ng/ml) and TNF-α (20 ng/ml). The graphs show Siglec-11 positive stained microglia cells. The 
strongest increase is detected after IFN-γ and TNF-α stimulation. The results shown in the graph are 
representative for 3 individual experiments. D Quantification of Siglec-11 expression on the cell surface 
of microglia. Treatment with TNF-α and IFN-γ significantly increased the Siglec-11 presence on the 
cells. The values are given as mean plus SEM of 3 individual experiments. Statistical analysis was done 
using SPSS software. Anova Bonferroni was chosen as test (✶✶✶=p≤0.001). Adapted and modified 
from PCT/EP2014/055445, Neumann et al, 2014. 
 
Untreated microglia showed positive staining for Siglec-11 on the protein level. Past 24 
hours of stimulation the amount of Siglec-11 in all tested types of microglia cells was 
increased. Compared to the untreated control (58.77+/-1.09 %) the values for TNF-α 
(79.4+/-1.45 %, p=0.001) and IFN-γ (74.43+/-1.2 %, p=0.001) treated cells were 
significantly increased. The ratios of Siglec-11 up-regulation on protein level were 
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similar to the data obtained from the Siglec-11 transcription level. None of the tested 
compounds down regulated the receptor indicating a permanent presence of Siglec-11 
on microglia independent of a pro- or anti-inflammatory environment (Figure 3.7 C and 
D). 
 
3.2.2 Detection and regulation of Siglec-11 in human macrophages 
The expression of Siglec-11 was not only found on microglia cells but also on 
macrophages (23), therefore it was an interesting question whether the receptor was 
regulated on macrophages in the same way as in microglia. In order to investigate this 
point the human macrophage cell line cell line THP1 was chosen. RNA transcription of 
Siglec-11 was detectable by RT-PCR in unstimulated macrophages similar to microglia 
(Figure 3.8 A).  
Up-regulation of transcription and protein expression was found in all tested conditions 
in the macrophages. Regulation of Siglec-11 was however not identical compared to 
the microglia cells. In the macrophages LPS led to the strongest increase of 
transcription and expression. TNF-α and IFN-γ that caused the most notable up-
regulation in microglia were less effective than LPS. IL-4 stimulation created a reaction 
that was close to the IFN-γ one. In detail 7.05 +/-1.72 fold for LPS, 2.27 +/- 0.42 fold for 
TNF-α, 3.7 +/- 0.34 fold for IFN-γ and 2.96 +/- 0.22 fold for IL-4 (Figure 3.8 B). 
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Figure 3.8 Detection and regulation of Siglec-11 in human macrophages: A Determination of 
Siglec-11 expression on RNA level in cells of the human macrophage line. GAPDH served as internal 
control. B Regulation of Siglec-11 on RNA level via quantitative RT-PCR in human macrophages after 
stimulation under different conditions for 24 hours. Cells were treated with IFN-γ (1000 U/ml), LPS (1 
µg/ml) IL-4 (20 ng/ml) and TNF-α (20 ng/ml). GAPDH served as internal control. The values are given as 
mean plus SEM of at least 3 individual experiments. Statistical analysis was done using SPSS software. 
Anova Bonferroni was chosen as test (✶=p≤0.05). C Determination of Siglec-11 regulation on the cell 
surface of macrophages via flow cytometry. Cells were stimulated with IFN-γ (1000 U/ml), LPS (1 µg/ml) 
IL-4 (20 ng/ml) and TNF-α (20 ng/ml). The graphs show Siglec-11 positive stained macrophage cells. 
The strongest increase is detected after IFN-γ and LPS stimulation. The results shown in the graph are 
representative for at least 3 individual experiments. D Quantification of Siglec-11 expression on the cell 
surface of macrophages. Treatment with LPS and IFN-γ significantly increased the Siglec-11 presence 
on the cells. The values are given as mean plus SEM of at least 3 individual experiments. Statistical 
analysis was done using SPSS software. Anova Bonferroni was chosen as test (✶=p≤0.05). Adapted 
and modified from PCT/EP2014/055445, Neumann et al, 2014. 
 
Flow cytometry experiments revealed a comparable regulatory pattern on the protein 
level of the macrophages following 24 hours of stimulation. Like the microglia a 
subpopulation of cells was found positive for Siglec-11 (27.93+/-4.0 %) without 
stimulation. Treatment with LPS (59.43+/-5.67 %, p=0.01), TNF-α (36.53+/-6.58 %), 
IFN-γ (55.77+/-6.03 %, p=0.04) or IL-4 (52.23+/-5.89 %) all increased the amount of 
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Siglec-11 on the macrophages similar to the ratios found on transcription level (Figure 
3.8 C and 3.8 D). 
 
3.2.3 Purification of defined fractions of PSA for Siglec-11 stimulation 
experiments 
To get a more detailed idea about the effects of the sialic acids on Siglec-11 
expressing immune cells it was necessary to stimulate the Siglec-11 receptor not only 
with a reagent consisting of molecules of various chain lengths (not separated PSA) 
but with fractions of more defined size. Therefore, the PSA was separated via an ion 
exchange column and subsequently investigated via polyacrylamid gel 
chromatography. The intention was to receive fractions with an average length of 20, 
60 and 180 sialic acid chains. Gel chromatography showed a successful separation of 
PSA and provided molecules of different sizes (Figure 3.9 A).  
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Figure 3.9 Purification of defined fractions of PSA for Siglec-11 stimulation experiments:  
A Separated fractions of PSA after lyophilization and solving in PBS on a polyacrylamide gel. The first 
middle and last 10-20% of the fractions were considered low (PSA-20), medium (PSA-60) and high 
molecular weight (PSA-180) PSA respectively and taken for experiments. The data were created in 
cooperation with Dr. Kappler and Norbert Rösel of the Biochemistry Department of the University of 
Bonn. B Size determination of PSA-20 against commercially available dextranes of known size. 
Fractionated PSA (Fractions 2-6) with an estimated average size of 7kDa (equal ≈ 20 chains) was 
collected and polyacrylamide gel based chromatography was performed. The PSA showed an average 
size of around 6-7 kDA therefore receiving the name PSA-20. Adapted and modified from 
PCT/EP2014/055445, Neumann et al, 2014. 
 
The first, middle and last 10-20% of the fractions received were taken for further 
experiments. The created groups were named PSA-20, -60 and -180 and represent 
low molecular weight, medium molecular weight and high molecular weight PSA. The 
effects of those different sized PSA molecules on Siglec-11 exhibiting cells on human 
microglia were of high interest for further experimental testing.  
The PSA with an average of 20 chains of sialic acid was further characterized by using 
Tris-Glycin gel chromatogrphy. Sulfated dextranes of known size were used as 
markers. PSA from fractions 3-5 presented an average size of 6-7 kDa. Since the 
molecular weight of a single sialic acid is known to be at 309 Da this result fitted well 
with our considered size of 20 sialic acid chains/molecule in average (Figure 3.9 B). 
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3.2.4 PSA treated microglia show size dependent alterations in cell proliferation 
and metabolic activity 
To test whether the application of PSA can be harmful to Siglec-11 expressing cells, 
various size lengths of sialic acids (mono-, tri- or hexa-sialic acid plus PSA-20, -60 and 
180) were added to cultured human microglia. The cells received different 
concentrations for 24 hours. Changes in proliferation and turnover per single cell were 
investigated. Proliferation of cells slightly increased under the impact of stimulation 
with commercial available mono-, tri- or hexa-sialic acid and PSA-20. Treatment with 
PSA-60 and -180 showed no difference of the values compared to the control cells. 
None of the differences found in proliferation between mono-, tri- or hexa-sialic acid 
and PSA-20, -60, -180 treated cells were significant (Figure 3.10 A). The metabolic 
activity of the cells was affected in a more notable way. Interestingly, stimulation with 
the shorter sialic acid molecules resulted in an increase of cellular turnover that was 
significant higher than that of the untreated control (tri-sialic acid 0.5 µM p=0.017 and 
1.5µM p=0.04, PSA-20 0.5 µM p=0.014 and 1.5 µM p=0.033). Concentrations of PSA-
60 and -180 showed in general MTT turnover values that were lower than those of 
mono-, tri- or hexa-sialic acid and PSA-20 stimulated cells. Furthermore, 1.5 µM of 
PSA-60 (0.7+/-0.05, p=0.012) and PSA-180 (0.74+/-0.04, (p=0.021) showed a 
significant lesser turnover value then the untreated control cells (Figure 3.10 B). 
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Figure 3.10 PSA treated microglia show size dependent alterations in cell proliferation and 
turnover: A Effect of different sizes of sialic acid in concentrations of 0.15, 0.5 and 1.5 µM on the 
proliferation of human microglia. 104 cells were stimulated for 24 hours with different kinds of sialic 
acids. Cells were counted via Neubauer chamber and normalized to control cells. The stimulation with 
the different kinds of sialic acids did not alter the cell proliferation of the microglia cells. B Effect of 
different sizes of sialic acid in concentrations of 0.15, 0.5 and 1.5 µM on metabolic activity. 104 cells 
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were stimulated for 24 hours with different kinds of sialic acids and metabolic activity was determined 
using an MTT assay system. Calculation was done with respect to the untreated control cells. Mono-,tri- 
and hexa-sialic acids as well as PSA-20 increased the metabolic activity of the microglia. PSA-60 and 
180 showed a decrease of the metabolic activity. C Determination of the toxic dose of PSA-20 for 
cultured human microglia. Concentrations from 0.005µM to 15mM were administered for 24 hours. 
Calculation was done with respect to the untreated control cells. Concentrations of 500 µM to 15 mM of 
PSA-20 decreased the metabolic activity of the microglia significantly. The values for A, B and C are 
given as mean plus SEM with at least n= 3 for all experiments. Statistical analysis was done using 
SPSS software. Anova Bonferroni was chosen as test (✶=p≤0.05, ✶✶p≤0.01, ✶✶✶=p≤0.001). Adapted 
and modified from PCT/EP2014/055445, Neumann et al, 2014. 
 
Based on the findings, PSA-20 was chosen for further cell culture experiments since it 
was showing no immediate negative effects on the microglia. To discover the 
limitations for cell culture experiments, cells were treated with a concentration gradient 
of PSA-20 reaching from 0.005 µM to 15 mM. Significant harmful effects were 
measured at 500 µM (0.38+/-0.01, p=0.001), 1.5 mM (0.54+/-0.02, p=0.001), 5 µM 
(0.46+/-0.02, p=0.001) and 15 mM (0.12+/-0.01, p=0.001). Interestingly, it required a 
total of 15 mM of PSA-20 to reduce the microglia turnover to a degree were no normal 
cell activity was left (Figure 3.10 C). With the generated data the half lethal dose 
(LD50) for PSA-20 was calculated for the human microglia by using Wolframalpha 
software. Via regression calculation the LD50 was found to be at 1724,73 µM of PSA-
20. 
 
3.2.5 PSA treated microglia show reduced TNF-α transcription after stimulation 
with LPS   
To test whether purified fractions of PSA could be used to stimulate the Siglec-11 
receptor, mono-, tri- or hexa-sialic acid plus PSA-20, -60 and 180 were added in three 
different concentrations (0.15, 0.5, and 1.5 µM) to cultured microglia cells. Since an 
immune modulating effect was expected from the ITIM linked Siglec-11 receptor LPS 
induced release of the pro-inflammatory cytokine TNF-α was chosen as readout of the 
PSA effect. Oligosialic acids consisting of 1, 3 or 6 chains of sialic acids and PSA-20, -
60 and -180 in combination with LPS were compared to LPS treated cells without sialic 
acid treatment (3.11+/-0.12 fold). None of the smaller molecules was showing a 
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significant reduction of the TNF-α levels past co-stimulation. Medium sized PSA-20 
abolished the LPS effect significantly at concentrations of 0.5 and 1.5 µM (0.5 µM = 
1.52+/-0.09 fold, and 1.5 µM = 1.23+/-0.08 fold). Also the PSA-60 stimulation of the 
microglia cells provided comparable results. Here a concentration of 0.15 µM showed 
significant differences (0.15 µM = 1.36+/-0.16 fold). Stimulation of microglia with both 
kinds of PSA molecules counteracted the LPS induced TNF-α release notably more 
efficient then the remaining variants of sialic acid. Treatment of the microglia with PSA-
180 also showed a suppression of TNF-α transcript however, without reaching 
significant levels (Figure 3.11 A). No significant effect of PSA-20 on TNF-α 
transcription by itself was found in additional control experiments with microglia (1.5 
µM PSA-20 = 1,16+/-0.14 fold, p = 1,000, data not shown). The results from the MTT 
and qRT-PCR experiments highlighted PSA-20 as most suitable form of sialic acids for 
further studies. Therefore, various concentrations of PSA-20 were administered to 
human microglia in order to study the ligand/receptor interaction in more detail.  
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Figure 3.11 PSA treated microglia show reduced TNF-α transcription after stimulation with LPS: 
A Modulating effect of PSA of different sizes on the transcription of the pro-inflammatory cytokine TNF-α 
in human microglia. A human microglia cell line was treated with LPS (1 µg/ml) and mono, tri, hexa sialic 
acid or PSA (0.15, 0.5, 1.5µM) for 24 hours. B Effect of PSA-20 on human microglia tested for a wide 
range (0.005-50 µM) of concentrations. All PSA-20 concentrations were added in combination with 
1µg/ml LPS to the cells. Gene transcripts for TNF-α were determined by quantitative RT-PCR and 
normalized to GAPDH for all data shown. The values for A and B are given as mean plus SEM of at 
least 3 experiments. Statistical analysis was done using SPSS software. Anova Bonferroni was chosen 
as test (✶=p≤0.05, ✶✶p≤0.01, ✶✶✶=p≤0.001). Calculations of statistics were done with respect to the 
LPS control. Adapted and modified from PCT/EP2014/055445, Neumann et al, 2014. 
 
In total nine different concentrations ranging from 0.005 µM to 50 µM were chosen. 
Tested concentrations of PSA-20 showed significant reduced levels of TNF-α 
transcripts starting at 0.05 µM or higher (Figure 3.11 B). 
Based on these findings the half maximal inhibitory concentration (IC50) was 
calculated via Wolframalpha software. The IC50 was determined by regression 
calculation to be at 0.09 µM of PSA-20. Taken together with the LD50 (1724.73 µM) 
from the cell metabolic activity experiments the therapeutic index of PSA-20 was 
calculated as LD50/IC50 = 19163,7 µM.  
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3.2.6 Siglec-11 knock-down in microglia shows an impaired PSA-20 effect  
To verify that the observed down-regulation of TNF-α transcripts was exclusively due 
to an interaction of PSA-20 with the Siglec-11 receptor on the human microglia a sh-
RNA mediated knock-down of the receptor was introduced.  
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Figure 3.12: Siglec-11 knock-down microglia show an impaired PSA-20 effect: A Determination of 
Siglec-11 reduction on the cell surface of human microglia via flow cytometry. The knock-down cells 
show around 85% less Siglec-11 presence than the control microglia. Data are representative for 3 
independent experiments. B Determination of the reduction of Siglec-11 transcription via qRT-PCR. 
Transcription level of Siglec-11 in the knock-down microglia are significantly reduced. Values are given 
as mean plus SEM of at least 3 experiments. Statistical analysis was done using SPSS software. The 
chosen test was a t-test of independent values (✶✶✶=p≤0.001). C Determination of the PSA-20 
mediated modulation of the TNF-α transcription via qRT-PCR. No significant PSA-20 effect was 
detectable anymore in Siglec-11 knock-down microglia. Values are given as mean plus SEM of at least 
3 experiments. Statistical analysis was done using SPSS software. Anova Bonferroni was chosen as 
test (✶=p≤0.05, ✶✶p≤0.01, ✶✶✶=p≤0.001). 
 
Efficiency determination revealed that on the cell surface of the microglia the presence 
of Siglec-11 was reduced by 85% (Figure 3.12 A). On RNA level around 65 % lower 
amounts of Siglec-11 transcripts were measured. The knock-down of Siglec-11 
transcription was significant in the microglial cells (0.35+/-0.07 fold, p=0.001), (Figure 
3.12 B). After successful confirmation of the knock down the microglia were co-
stimulated with PSA-20 and LPS and compared to control cells transduced with a non-
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targeting vector plasmid. To determine the effect of the knock-down, qRT-PCR tested 
modulation of TNF-α transcription was chosen. The control cells showed increased 
TNF-α transcription level after addition of LPS (5.01+/-0.63 fold) and significant 
reduced values after LPS/1.5 µM PSA-20 co-stimulation (2.85+/-0.28 fold, p=0.006). 
The LPS/PSA-20 treated knock-down cells showed no reduction of TNF-α transcription 
compared to the LPS stimulated knock-down microglia. The difference in TNF-α 
transcription between LPS/PSA-20 stimulated knock-down (4,49+/-0.45 fold) and 
control microglia (2.85+/-0.28 fold) was significant as well (p=0.018). Without sufficient 
amounts of the Siglec-11 receptor present the PSA-20 mediated effect was hardly 
detectable in the microglia (Figure 3.12 C). 
 
3.2.7 Human macrophages show reduced TNF-α transcription after stimulation 
with LPS/PSA-20   
Since the low molecular weight PSA-20 reduced the LPS-induced gene transcription of 
TNF-α at a concentration of 0.15 µM, 0.5 µM and 1.5 µM in the human microglia very 
effectively the same paradigm was tested with the human macrophages. LPS induced 
increase of TNF-α in macrophages (3.57+/-0.06 fold) similar to microglia levels. Two of 
the three tested LPS/PSA-20 concentrations showed a significant down-regulation of 
TNF-α transcripts (0.15 µM = 2.36+/-0.24 fold, p=0.022 and 1.5 µM = 2.31+/-0.4 fold, 
p=0.016) when compared to LPS alone.  
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Figure 3.13 Human macrophages show reduced TNF-α production after stimulation with 
LPS/PSA-20: Effect of low molecular weight PSA (PSA-20) on the pro-inflammatory cytokine TNF-α in 
human macrophages. The human macrophage cell line THP-1 was treated with LPS (1 µg/ml) and PSA-
20 (0.15 µM, 0.5 µM, 1.5 µM) for 24 hours. Gene transcripts for TNF-α were determined by quantitative 
RT-PCR and normalized to GAPDH. Compared to LPS, the TNF-α transcription was significantly 
reduced when co-treated with LPS and 0.15 µM or 1.5 µM PSA-20. Values are given as mean plus SEM 
of 4 independent experiments. Statistics were performed using SPSS software. Anova Bonferroni was 
chosen as test (✶=p≤0.05). Adapted and modified from PCT/EP2014/055445, Neumann et al, 2014. 
 
Values of 0.5 µM PSA-20/LPS co-stimulation were not found to be significantly lower 
than the LPS reference (Figure 3.13). The results were quite comparable to those 
received from the human microglia experiments.  
 
3.2.8 PSA-20 modulates phagocytosis in Siglec-11 positive microglia and 
macrophages 
Phagocytosis is one of the key features performed by activated macrophages and 
microglia. Therefore, it was an interesting question whether PSA-20 would be capable 
of modulating phagocytosis in LPS treated cells. Macrophages and microglia were 
challenged with the same LPS/PSA-20 co-stimulation procedure as before and the 
phagocytosis capacity was determined via uptake of fluorescent latex beads.  
No activating effect of PSA-20 on bead uptake was found in additional control 
experiments with microglia cells (1.5 µM PSA-20 = 87.45+/-0.74 % of control, data not 
shown). The stimulation with LPS increased the bead phagocytosis of microglia 
(141.63+/-4.93 %) and of macrophages (145.03+/-6.08 %) compared to untreated 
control cells. Both cell types showed less uptake when co-treated with LPS and PSA-
20 compared to the LPS control. Microglia bead phagocytosis was 124.86+/-7.21%, 
122.8 +/-8.62 % and 108.05+/-1.32 % for 0.15, 0.5 and 1.5 µM PSA-20/LPS treatment 
(Figure 3.14 A). Macrophages showed 118.39+/-4.34 %, 107.27 +/-6.34 % and 
104.55+/-2.95 % of phagocytosis for 0.15, 0.5 and 1.5 µM PSA-20/LPS stimulation 
respectively (Figure 3.14 B). Engulfment of beads was significantly decreased at 1.5 
µM PSA-20 (p=0.004) in microglia. In macrophages stimulation with 0.15 µM 
(p=0.022), 0.5 µM (p=0.002) and 1.5 µM PSA20/LPS (p=0.001) led to significant lower 
phagocytosis levels as well. 
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A Human microglia 
 
 
B Human macrophages 
 
 
Figure 3.14 PSA-20 modulates phagocytosis in Siglec-11 positive microglia and macrophages: 
Engulfment of fluorescent latex beads by human microglia (A) and macrophages (B). The cells were 
treated for 24 hours with either LPS or LPS in combination with different concentrations of PSA-20. The 
beads were added for 1 hour before measurement. The values of the untreated samples were 
normalized to 100% serving as reference for all other groups. In microglia combination of 1.5 µM PSA-
20/LPS led to significant reduced levels of bead engulfment compared to LPS. In macrophages all 
tested LPS/PSA-20 combinations were showing significant lower levels of bead phagocytosis. Data for 
A and B are shown as mean plus SEM with n=4 independent experiments for microglia and n= 3 
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independent experiments for macrophages. Statistics were performed using SPSS software. Anova 
Bonferroni was chosen as test (✶=p≤0.05, ✶✶p≤0.01, ✶✶✶=p≤0.001).  
 
3.2.9 Siglec-11 expression in a transgenic mouse model  
To investigate the effect of human Siglec-11 in the inflammatory processes in vivo a 
Siglec-11 transgenic mouse model (created by Dr. Yiner Wang) was used. For 
characterization of the Siglec-11 expression in the mice, RT-PCR and flow cytometry 
analysis was performed.  
Tissue samples originating from brain, spinal cord, liver, spleen, bone marrow and 
blood of Siglec-11 transgenic mice and littermate controls were harvested. Transcripts 
of Siglec-11 were detected in the brain, liver and spleen tissue but not in the spinal 
cord, bone marrow or blood of Siglec-11 mice. None of the samples from the control 
mice showed any kind of Siglec-11 transcription (Figure 3.15 A).  
For the flow cytometry experiments full organ cell homogenate was created and 
stained against Siglec-11. Here again, cells from brain, spleen and liver tissue but not 
spinal cord, bone marrow or blood presented a shift when tested for presence of 
Siglec-11. Like in the PCR experiments no proof for the presence of Siglec-11 on 
protein level was detected in cells originating from the littermate control animals 
(Figure 3.15 B).  
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Figure 3.15 Siglec-11 expression in a transgenic mouse model: A Detection of Siglec-11 in brain, 
liver and spleen samples from Siglec-11 transgenic mice but not Bl6 control mice via RT-PCR. GAPDH 
was used as internal control. Brain, liver and spleen samples of Siglec-11 mice showed transcripts of 
Siglec-11. B Flow cytometry based detection of Siglec-11 in a mouse model. Siglec-11 is present on the 
cell surface of brain, liver and spleenocytes of Siglec-11 transgenic mice. No positive signal was found 
in the control mice. C Detection of primary microglia originating from Siglec-11 transgenic and littermate 
control mice via flow cytometry. Siglec-11 is found on microglia cells from the Siglec-11 transgenic mice. 
The results shown in A, B and C are representative for 3 individual experiments. The mice used in the 
experiments were generated by Dr. Yiner Wang (107). 
 
3.2.10 PSA-20 treated Siglec-11 transgenic mice show reduced expression of 
inflammatory markers after LPS application 
To investigate the effect of PSA-20 in vivo a Siglec-11 transgenic mouse line was used 
in a model of systemic inflammation. Therefore, Siglec-11 transgenic mice and 
littermate control mice received 4x PBS, LPS and/or PSA-20 LPS or (1 µg/g 
bodyweight) 4 days in a row with 24 hours between each treatment. 24 hours past the 
last injection the animals were sacrificed and brain and spleen samples were taken for 
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further investigation. Brain and spleen tissue were used for RNA isolation and 
subsequent qRT-PCR analysis. The cytokines of interest for the experiments were 
TNF-α, IL1-β as well as the microglia/macrophage marker Iba1.  
The Siglec-11 PBS controls in brain and spleen showed no up-regulation of the 
inflammatory cytokines during the duration of the experiments and levels were equal to 
the PBS littermate controls. The Siglec-11 positive brain samples from mice that 
received LPS treatment but no PSA-20 showed reduced lower transcription levels of 
TNF-α and IL1-β compared to the LPS treated littermate controls. The Iba1 regulation 
of those samples was similar to the LPS control mice.  
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Figure 3.16 PSA-20 treated Siglec-11 transgenic mice show reduced leverls of inflammatory 
markers after LPS application : Quantification of IL1-β (A), TNF-α (B) and Iba1 (C) transcription in 
mouse brain and spleen tissue via qRT-PCR. The mice used in the experiments were generated by Dr. 
Yiner Wang (107). Animals were injected 4x with 1 µg/gbw within 96 hous with a combination of LPS 
and PSA-20. Regulation of TNF-α, IL1-β and Iba1 was compared to PBS treated animals using GAPDH 
as internal control. Treatment of PSA-20/LPS showed significantly reduced level of TNF-α transcripts in 
the brain. Iba1 regulation was significantly reduced in brain and spleen past PSA-20/LPS treatment. 
Statistics were performed using SPSS software. Anova Bonferroni was chosen as test (✶=p≤0.05, 
✶✶p≤0.01, ✶✶✶=p≤0.001). The values are given as mean plus SEM of n = 3-5 mice per condition. 
Adapted and modified from PCT/EP2014/055445, Neumann et al, 2014. 
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Notable differences in transcription levels of TNF-α, IL1-β and Iba1 were detected in 
the brain tissue of the animals challenged with the combination of LPS and PSA-20 
(Figure 3.16 B and C).  
The transcription of TNF-α in LPS/PSA-20 co-stimulated mice was significantly 
reduced compared to the LPS littermate (p=0.006) and LPS Siglec-11 (p=0.001) mice. 
Iba-1 transcription in the brain was impaired after LPS/PSA-20 treatment compared to 
the LPS/PSA-20 co-stimulated littermate control mice (p=0.023). The measurement of 
the spleen derived material showed different responses to the PSA-20 treatment. TNF-
α and IL1-β levels were reduced but not significantly different in the LPS/PSA-20 
treated mice. Values of Iba1 in Siglec-11 positive LPS/PSA-20 treated mice were 
significantly reduced against the LPS injected control (p=0.003) and Siglec-11 mice 
(p=0.001). The LPS/PSA-20 treated control mice presented decreased Iba1 
transcription (p=0.001) as well (Figure 3.16 C). 
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4. Discussion 
 
4.1 Importance of Siglecs 
4.1.1 Siglecs in therapeutic approaches 
This project was aiming to study Siglec mediated actions of microglial cells in 
neuroinflammation. Since Siglecs are linked to ITAM or ITIM structures one Siglec 
receptor of each kind was chosen. The potential of Siglec-11 and Siglec-H for therapy 
strategies was of particular interest for the investigation. 
Due to their involvements in numerous essential regulatory processes, Siglecs are 
very important for the maintenance of homeostasis and orchestration of various 
cellular activities (42). Moreover, malfunctioning of Siglecs can also exaggerate 
inflammatory reactions which may among others foster autoimmune diseases (35). 
Therefore, it is not surprising that within the last years more and more approaches 
were initialized that are focusing on Siglecs as potential key targets for 
pharmacological strategies. Until now, the majority of projects involve antibody-based 
approaches. At the moment the most successful antibody therapy strategies are all 
aiming at inhibitory Siglecs.   
Siglec-2 (CD22) was among the first to be studied. Since it is constitutively expressed 
on B-cells Siglec-2 offers a major potential for immunotherapy of B-cell malignancies 
and autoimmune diseases (68, 69). A line of clinical trails include toxin conjugated as 
well as naked antibodies (68-70). The humanized monoclonal antibody eratuzumab 
was shown to internalize into the cell after binding to the Siglec-2 receptor. These 
results brought about opportunities to carry out interesting experiments involving 
conjugation with toxins, cytotoxic drugs or radionucleotides (71). Currently, 
eratuzumab is tested with respect to treatment of non-Hodgkin lymphoma and 
systemic lupus erythematosus (72). Another Siglec that was identified as useful target 
was Siglec-3 (also called CD33). The receptor is constitutive expressed on cells 
belonging to the hematopoetic system. It is intensively investigated in relation to acute 
myeloid leukemia. However, despite a line of different phase III studies no antibody 
therapy based approach was found so far that showed a clear benefit for the patients 
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(73-75). In fact, several studies had to be discontinued due to developments of severe 
side effects or an outcome that was worse than that of the control group (73, 74). 
Apart from the pure antibody therapy the novel technology of Siglec glycotargeting is 
gaining more attention. The underlying concept is called targeted drug or gene delivery 
(76). Carbohydrate-covered drugs or receptor blocking/crosslinking molecules can be 
applied to inhibit or foster Siglec functions. The induction of apoptosis of eosinophil 
granulocytes is currently under investigation and represents a promising approach to 
pharmacologically address allergic diseases (77). Although the proof of principle for 
this technology is given, it is at the moment far from being clinical applicable. 
Despite substantial investment of money, time and the undeniable potential, only a 
minor part of the Siglec receptors are currently enrolled in studies including a therapy 
strategy. Furthermore, none of the ITAM associated Siglec receptors was until now 
seriously investigated in terms of being a target for therapy. Although some of the most 
advanced data available at the moment are derived from antibody based strategies 
they often fail to provide a clear benefit for the patient or are linked to severe side 
effects. Therefore, it is essential to extend the search for strategies on how to use the 
potential offered by the Siglec receptor family more efficiently. 
 
4.2 Presence and function of Siglec-H on microglial cells 
4.2.1 Siglec-H expression and regulation on microglia 
Zang and co-workers first characterized the murine receptor Siglec-H in 2006 (47). 
Initially, it was considered to be a cell surface marker present on PDCs (29, 46). Later 
Siglec-H was also identified on subsets of macrophages in spleen and lymph nodes. 
Compared to other members of the receptor family Siglec-H is relatively small and 
lacks like Siglec-15 its own cytoplasmic signaling domain. Both receptors are 
mediating signaling via the ITAM linked adapter protein DAP12. No ligand could be 
determined for Siglec-H so far. However, experiments suggest an involvement of 
Siglec-H in endocytosis (47). When the interaction of PDCs with T-cells was 
investigated Siglec-H was found to participate in the orchestration of T-cell mediated 
inflammation and antigen delivery (48, 78).  
Discussion 
 
 
 74 
Little is known about the role of DAP12 associated Siglecs in general and Siglec-H in 
particular regarding functions in innate immunity. Therefore, the basic idea was to 
investigate whether the receptor was detectable in the CNS on microglial cells. 
Furthermore, the study was aiming to receive additional insights in the functions of the 
protein in neuroinflammation. Siglec-H was found to behave different in microglial cells 
then in PDCs. It was not constantly expressed but up-regulated after defined stimuli. 
The microglia were challenged with pro-inflammatory factors in order to activate 
Siglec-H. From all reagents tested only IFN-γ or a combination of LPS and IFN-γ led to 
a detectable band. These findings were also confirmed on protein level via flow 
cytometry. Why the regulation is different between the PDCs and the microglia is an 
interesting question. It is possible that the answer lies in the two different locations of 
residence of both cell types. PDCs are present within the lymphatic organs or the 
blood stream. In those environments they are permanently exposed to pathogens and 
subsequently to T-cells during the process of antigen presentation. Microglia on the 
other hand are located in an immune privileged area were under normal conditions no 
or very little pathogens should be present. Thus, a constant presence of the receptor is 
maybe not necessary on the cell surface of the microglia. However, in case of sensed 
disorder that leads to the release of IFN-γ the up-regulation of Siglec-H possibly 
provides the microglial cell with an additional tool to deal with the source of the 
disorder.  
 
4.2.2 Functions of Siglec-H   
DAP12 associated receptors have been shown to play important roles in microglial 
phagocytosis (79, 80). More information is gathered with respect to the signaling 
cascade, ligands and functions of the receptors. Still little is known about the ligand 
and function of Siglec-H. In fact Siglec-H is the only member of this family that is not 
associated with any carbohydrate ligand so far (47).  
The glycosylation pattern on the surface of cells varies dependent on cell type and 
activation state. Dramatic alterations of the glycostructure can be found on cells during 
tumor progression and malignancy (81). Recent studies reveal a connection between 
lectin–glycan interactions and the regulation of tumor microenvironments (82). One 
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characteristic of cancer cells is an increased expression of sialic acid residues on their 
cell surface (83). Furthermore, cancer cells express abnormal glycans on their 
surfaces, which are meanwhile in parts well characterized, and serve as biomarkers in 
cancer (84, 85). Some of these tumor-associated glycobiomarkers like the sialyl-Tn 
antigen, which is abnormally expressed in several types of cancer, is recognized by 
the DAP12 associated receptor Siglec-15 (85).  
The performed experiments in this thesis now link Siglec-H with binding to glioma cells, 
but not to astrocytes or any other normal mouse cells tested. Although the function of 
Siglec-H in various aspects is unclear it has been previously described to execute the 
uptake of antigens (46, 47). Indeed Siglec-H on microglia showed the capability to 
specifically mediate engulfment of beads under pro-inflammatory IFN-γ stimulation in 
the performed experiments. In combination with the selective binding of the Siglec-H 
Fc fusion protein to glioma cells the data suggest that microglia can recognize and 
phagocytose malignant cells via the Siglec-H receptor. Although the precise molecular 
structures recognized on the glioma cells are unclear there are interesting similarities 
to human Siglec-15. Mouse Siglec-H and the structural similar human Siglec-15 
appear both to recognize and fight of tumor cells. This would suggest an involvement 
of this DAP12 associated receptors in recognition and removal of cells that have 
undergone malignant changes. In this regard the fact that none of the regular α2-3, α2-
6 or α2-8 linked sialic acids could be identified as ligands for Siglec-H is particularly 
interesting. It is very well possible that what they recognize is not a regular linked sialic 
acid but a variation caused by a mutation in the malignant cells that is not found in 
healthy cells.  
Siglec-H is so far known for modulation of IFN-α release (29, 86). This new data 
provide solid hints regarding additional functions of ITAM signaling Siglec receptors. If 
confirmed in general these data would provide options for therapeutic strategies 
involving DAP12 associated Siglecs in cancer biology.  
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4.3 Siglec-11 interaction with sialic acids in neuroinflammation  
4.3.1 PSA-20 a promising Siglec-11 ligand 
Over the recent years increasing insights have been gained regarding the importance 
of glycobiology in various pathologies. Siglecs as receptors of sialic acids have been 
found to be involved not only in the maintenance of homeostasis but also in multiple 
immune relevant processes (43). Siglecs are also of high importance in all kinds of 
diseases including cancer, infectious or autoimmune reactions (35, 85, 87). As 
mentioned earlier, based on this knowledge substantial effort was initialized to develop 
therapeutic strategies involving Siglecs. However, most of the ideas follow 
conventional antibody based strategies, which often failed to provide beneficial results 
for the patients (21). No attempt aimed to make direct use of sialic acids as the natural 
ligand of the Siglec receptor family. 
When Siglec-11 was discovered in 2002 low but distinct presence of Siglec-11 was 
detected via immuno-histochemical staining in a line of tissues. Expression of the 
protein was identified in microglial cells, Kupffer cells in the liver, intestinal lamina-
propria macrophages, and perifollicular cells in the spleen, as well as in cells from 
tonsils and appendix (23). Recently, investigation of the ITIM exhibiting Siglec-11 was 
started with respect to neuroinflammation (51). Wang and co-workers used murine 
primary microglial cells that were transduced with a lentiviral vector to over-express a 
flag-tagged human Siglec-11 receptor variant. Stimulation of Siglec-11 by cross-linking 
with flag-specific antibodies led to the down-regulation of important pro-inflammatory 
cytokines in LPS treated microglia. Furthermore, neuroprotective effects of the Siglec-
11 receptor were found in a neuron microglia co-culture system (51). The experimental 
approach used provided exciting data regarding the function Siglec-11 and highlighted 
it as promising target for therapy strategies. The disadvantage was that the flag-based 
approach was relative artificial. 
To overcome this issue stimulation with soluble α2.8-linked PSA was chosen to further 
study the role of Siglec-11 in neuroinflammation (23). Microglia are, while patrolling the 
CNS, constantly exposed to sialic acids that represent an essential part of the cellular 
glycocalyx (88). In a healthy environment microglia should therefore constantly receive 
signals by sialic acid interactions with Siglec-11 that prevent them from getting 
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activated. Since sialic acids are regular participants in various cell-cell interactions (3, 
89), contact to PSA could be considered by the immune cells as a sign of a not 
endangered area. Due to the receptor cross-linking data the assumption was that 
stimulation of Siglec-11 with PSA should initialize anti-inflammatory signaling. 
The data generated in vitro highlight that different sizes of PSA do not have uniform 
effects on the cells. Short-chained sialic acids and PSA-20 are not affecting the cell 
metabolic activity in a negative way while PSA-60 and -180 reduced the metabolic 
activity of the cells. Apparently, the intensity of the signaling depends on the size of the 
sialic acids. It is more than likely that a certain concentration of larger sialic acid 
molecules is creating an amount of ITIM-linked signaling that has harmful 
consequences. This might occur via simultaneous activation of several Siglec-11 
receptors by one sialic acid. If the inhibitory signals are too extensive the cell might 
shut down mechanisms, affecting the metabolic turnover like shown by the MTT assay. 
This would mean that cells are more capable to tolerate exposure to shorter sialic 
acids. To validate the PSA-20 effects observed in microglia a repetition of the 
metabolic turnover experiments using other Siglec-11 positive cells like macrophages 
should be performed.  
Furthermore, not only metabolic activity but also inflammatory reactions were affected 
differently by sialic acids of various sizes. PSA-20 and PSA-60 counteracted the up-
regulation of TNF-α transcripts in LPS stimulated microglia in a significant way. To a 
minor degree PSA-180 also showed this tendency. The fact that the mono-, tri- or 
hexa-sialic acids failed completely to dampen the LPS induced increase of TNF-α 
transcription suggests that also a minimum size is required to initialize a successful 
signaling. It is clear that the parameters investigated so far are not sufficient to cover 
the full spectrum of possible PSA reaction mechanisms appropriate. Nevertheless, the 
cell metabolic activity and TNF-α transcription data give evidence that the size of the 
PSA is a crucial point that has to be considered carefully if PSA is to be used for 
therapeutic purposes. Hence, for further experiments the short but still effective PSA-
20 was the clear favorite. 
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4.3.2 PSA-20 a modulator of inflammation  
The fact that stimulation of LPS co-treated microglia or macrophages with PSA-20 
impaired the transcription of TNF-α was highly interesting with respect to treatment 
opportunities. Binding and downstream signaling of the cytokine with one of its cognate 
receptors, TNF-RI or TNF-RII, modulates fundamental processes in neuroinflammation 
including, gliosis, demyelination, blood–brain-barrier deterioration and neuronal cell 
death (90, 91). Furthermore, TNF-α has been shown to play an important role in 
systemic inflammation as well as in multiple sclerosis. Both pathologies are leading to 
severe cases of neuroinflammation and so far therapeutic approaches like TNF-α 
depletion often failed to provide satisfying results (87). In studies involving acute and 
chronic inflammation the effects of an anti-TNF-α therapy were not uniform as well. In 
sepsis a blockade of the cytokine worsened the conditions (87). On the other hand, it 
was found to be a very promising approach in rheumatoid arthritis (92). The potential 
of PSA-20 was revealed by the fact that it did not only affect TNF-α but was effective in 
a more general way. Since the reasons for the inflammation associated damage in 
diseases are rarely due to only one factor but often interact and enhance each other 
this feature is essential in order to have a certain treatment flexibility. 
Experiments with microglia as well as with macrophages revealed that PSA-20 was 
significantly affecting phagocytosis as another key element of immune cell activation. 
Microglia can not only engulf apoptotic cells in inflamed tissues but also clear cellular 
debris/synapses during neuronal remodeling processes (93). Microglia are also 
capable to engulf stressed but viable neurons during inflammatory diseases (93, 94). 
Independently from each other several laboratories showed that in inflammation the 
ability of microglia to discriminate between living and dead neurons is impaired. As a 
consequence LPS or amyloid-β activated immune cells attacked healthy cells and 
reduced the numbers of neurons via phagocytosis (95). Administration of 1.5 µM PSA-
20 was enough to decrease the transcription of TNF-α and the phagocytosis activity of 
microglia and macrophages significantly. Both cell types are highly involved in various 
inflammation-linked diseases within the CNS (96). If PSA-20 prevents uncontrolled 
exposure of neuronal structures to TNF-α and phagocytosis this could result in less 
damage to the cells. Since the dose used in the experiments is relative low there is 
also very little danger that the endogenous molecules cause negative effects by 
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themselves. Moreover, the sh-RNA based knock-down experiments proved a specific 
relation of PSA-20 binding to Siglec-11 and the observed impairment of inflammation. 
In summary the administration of PSA-20 to microglia and macrophages in cell culture 
experiments revealed substantial potential of the compound for anti-inflammatory 
treatment strategies. 
 
4.3.3 Therapy of inflammation by sialic acids in disease models  
Since the in vitro approach is always insufficient to test the potency of an experimental 
procedure animal models were required to further investigate the Siglec-11 interaction 
with PSA-20. In medicine bacterial sepsis, a systemic inflammatory response 
syndrome caused amongst others by LPS exposure is responsible for millions of 
deaths worldwide (97). Over time the inflammatory response caused by the invading 
pathogens gets out of balance leading to severe tissue damage (98). The longer pro-
inflammatory markers persist the more harm they can cause. In case of TNF-α 
pathological alteration of lipid and glucose metabolism have been described (99).  
A murine animal model of chronic inflammation induced by LPS injection was therefore 
an interesting tool to investigate the PSA-20 effect on TNF-α and other relevant 
inflammation markers like IL1-β and Iba1. The acquired data show a very strong 
suppression of TNF-α transcription levels in the brain while the spleen was not 
affected. IL1-β was neither modulated in the brain nor in the spleen in a notable way. 
Finally, Iba1 showed a decrease of transcripts that was exclusive to the spleen. The 
effect of PSA-20 on the regulation of the investigated genes was not uniform but 
selective and is therefore different to the effect of for example corticosteroids. The use 
of this inflammation-modulatory compound in sepsis is highly controversial since it is 
unclear when and under what circumstances it is beneficial. Additionally, 
corticosteroids act very unspecific and can present severe side effects (100). Hence, 
the application of PSA-20 could provide an option to modulate the TNF-α linked 
inflammatory processes during infectious events and chronic inflammation. 
Furthermore, the interference with the immune system would occur in a less stressful 
way then for example TNF-α depletion treatment (99). 
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Phagocytosis of healthy cells due to misjudgment during inflammation has been 
reported recently (95). Although, not investigated in our mouse model it is not far-
fetched to speculate that the PSA-20 induced reduction of phagocytosis observed in 
cell culture experiments could also be happening in vivo. To allow a more qualified 
statement more inflammation relevant cytokines and receptors need to become 
investigated in the future to understand better what effects are restricted to the CNS 
and which are relevant for other organ sides. Furthermore, it is always important to 
keep in mind, that it is never possible to transfer in vitro data 1 to 1 to the in vivo 
situation. The selectivity of the PSA-20 treatment could allow very localized treatment 
without danger of offside effects. 
 
4.3.4 Outlook 
Besides the investigated model of systemic inflammation there are several other 
disease models that appear to be highly promising for PSA-20 testing. One of them is 
the model of experimental autoimmune encephalomyelitis (EAE). In previous EAE 
experiments including anti TNF-α approaches, application of anti-TNF-α or sTNF-α 
receptor antibodies attenuated the disease (101, 102). Studies have demonstrated that 
TNF-α is crucial in the early stages of EAE, whereas in later phases other mechanisms 
are dominating. According to literature, TNF-α may be more essential for initial 
leukocyte homing rather than progression of later stage disease (103). TNF-α levels 
measured in the CSF of patients suffering from multiple sclerosis were abnormally high 
and correlated with disease severity and progression (104, 105). TNF-α was found to 
be involved in myelin and oligodendrocyte deterioration, lymphocyte infiltration, 
astrocyte activation, and the up-regulation of MHC I and II molecules on CNS resident 
cells, thereby triggering T-cell responses. Despite the increasing knowledge about the 
beneficial effects of TNF-α suppression, all antibody-based studies tried so far were 
ineffective or had severe side effects. Therefore, tackling the problem from a different 
angle appears to be necessary. PSA-20 is an endogenous molecule that showed no 
harmful effects in cell culture systems. It should cause none of the undesired 
consequences observed in antibody-based therapies. Furthermore, the concentration 
of PSA-20 that was required to generate significant data in the different experimental 
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systems is quite low. This would mean that also the metabolism needs to be 
challenged with a dose that is easy to handle and so less stressful for the patient. One 
possible limitation of PSA-20 usage in multiple sclerosis is the fact, that TNF-α is only 
an essential factor in the beginning of the disease. It could be a very good treatment 
option if multiple sclerosis is recognized early enough. Measurement of TNF-α levels in 
PSA-20 treated EAE mice at different time points would be most interesting to 
determine the best time point for the application. Given that the undesired increase of 
the cytokine could be stopped milder clinical outcome in patients that received PSA-20 
at the very onset of symptoms could be achieved. Later during the disease PSA-20 
administration might be less effective. This is however a point that has to be 
investigated intensively in future experiments. 
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5 Summary 
 
Sialic acid binding Siglecs are involved in various pathological processes. A minor 
fraction of Siglecs mediates activating signals via the ITAM linked DAP12 adaptor 
protein while the majority of Siglecs modulates inflammatory reactions via ITIM units. 
Siglec-11 and Siglec-H are both expressed on microglia cells but exhibit structural and 
functional differences. To get a better understanding about the function of Siglecs in 
microglia, one Siglec linked to ITAM and one linked to ITIM structures were studied. 
In cell culture experiments the ITAM associated murine Siglec-H receptor was up-
regulated after IFN-γ stimulation or IFN-γ/LPS co-stimulation in primary and cell line 
microglia. Microglial cells showed Siglec-H mediated engulfment of latex beads under 
pro-inflammatory conditions. Furthermore, a Siglec-H fc fusion protein bound to 
structures on two independent glioma cell lines while it did not bind control cells in in 
vitro experiments. Human Siglec-11 that exhibits an ITIM domain in its cytoplasmic tail 
is constitutively expressed on microglia and macrophages. The receptor was up-
regulated after pro- and anti-inflammatory stimulation. Via heat mediated hydrolysis 
and subsequent separation using a HPLC system, α2-8 linked sialic acid molecules 
with a length of around 20, 60 and 180 sialic acid chains were generated. Treatment 
with the different sizes of sialic acids revealed a chain length of around 20 sialic acids 
(PSA-20) to not cause harmful effects on the metabolic activity at concentrations of 
0.15 µM, 0.5 µM and 1.5 µM. Post stimulation with PSA-20, a down-regulation of TNF-
α transcription and phagocytosis activity was detected in microglia and macrophage 
cell lines. For in vivo experiments a Siglec-11 transgenic mouse line expressing Siglec-
11 in the brain, spleen and liver was used. When the Siglec-11 mice were used in a 
model of chronic inflammation, PSA-20 mediated suppression of TNF-α transcription in 
the brain was successfully detected. The data reveal sophisticated functions of the two 
investigated Siglecs regarding recognition of disturbances and modulation of 
inflammatory reactions in the CNS. Therefore, the Siglec receptors represent 
interesting research targets that can increase understanding of the Siglec mediated 
defense against malignant cells and the modulation of inflammation in the CNS. 
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